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ABSTRACT
Involvement of Adenosine A1 receptors in systemic inflammation and altered
vascular reactivity in allergic mice
Dovenia S. Ponnoth

Epidemiological studies have established that people who have lung diseases such
as asthma and COPD are likely to develop adverse cardiovascular events. While the
reason for this has not been elucidated, it is believed that inflammation could be the key
component linking the two conditions. Adenosine, an endogenous purine nucleoside, has
been strongly implicated in asthma pathophysiology and also has potent effects on the
cardiovascular system. This work was undertaken to gain a better understanding of the
relationship between asthma and its cardiovascular effects, and more specifically the
possible role adenosine plays under these conditions.
We hypothesize that asthmatic lung inflammation translates into systemic
inflammation and alters vascular responses where adenosine plays an important role.
Therefore, this study investigated the effects of aerosolized adenosine, used to elevate
lung adenosine levels, on vascular reactivity and inflammation in a well established
mouse model of allergic asthma established in our lab. We found that allergic mice had
poor vasorelaxation to adenosine and systemic inflammation, in addition to lung
inflammation, and aerosolized adenosine exacerbated these effects. Data indicated a
possible role for A1 adenosine receptor (AR) in altered vascular reactivity and
inflammation. Based on these findings, we next studied the effects of adenosine using
genetically modified mice in which the A1 AR gene was deleted (A1KO) and
corresponding A1 wild-type(A1WT) mice, in which the A1 receptor was present.
Allergic A1KO mice had no systemic inflammation, and the adenosine-mediated
vasorelaxation responses obtained were comparable to non-allergic mice. Aerosolized
adenosine also did not have any effect in A1KO mice. On the other hand, allergic A1WT
mice had lower aortic relaxation response to non-selective adenosine analog NECA,
presence of significantly higher levels of inflammatory cytokines in plasma and higher
airway responsiveness to NECA, compared to non-allergic A1WT controls and all groups
of A1KO mice, with aerosolized adenosine exacerbating all these responses. From these
data, it can be concluded that asthmatic mice had poor vascular responses and
inflammation, possibly mediated through the A1 AR.
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CHAPTER ONE

INTRODUCTION
Adenosine is an endogenous purine nucleoside with multiple physiological effects
and is produced by all cells. Figure 1.1 shows the chemical structure of adenosine. Some
of its regulatory activities are vasodilation of the coronary vessels, including under
ischemic conditions, neuromodulation especially in the sleep-wake cycle, effects on the
heart including regulating inotropy, chronotropy and many others (Fredholm, 2007).
Generation of adenosine and its metabolism
Under normal physiological conditions, adenosine is formed by the intracellular
conversion of S-adenosyl-L methionine (SAM) to S-adenosyl-L-homocysteine (SAH).
This moiety is then converted to adenosine and homocysteine by SAH-hydrolase
(Deussen et al., 1989; Pelleg and Porter, 1990). Adenosine can also be produced
extracellulary through successive dephosphorylation of ATP; ATP is dephosphorylated to
ADP and then AMP which is converted to adenosine via ecto-5’-nucleotidases
(Bardenheuer and Schrader, 1986; Forsythe and Ennis, 1999). Adenosine thus produced
can be further converted to inosine by the enzyme adenosine deaminase (ADA) and
finally is broken down to uric acid which is excreted in urine. There is another pathway
through which adenosine is re-converted to AMP via the enzyme adenosine kinase (AK).
In addition to being metabolized, adenosine can also act on specific receptors to induce
various physiological effects. Figure 1.2 shows the metabolic processes of adenosine
production and breakdown. Extra-cellular concentrations of adenosine are elevated
several fold during periods of increased metabolic demand, injury or stress such as
ischemia (Sparks and Bardenheuer, 1986).

2
Figure 1.1 Structure of adenosine
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Figure 1.2 Metabolic pathways of adenosine
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Adenosine receptors
Adenosine produces various effects through cell surface purinergic receptors and
thus far, 4 subtypes have been identified: A1, A2A, A2B and A3. All four receptors are Gprotein coupled and the effects that adenosine produces depends on both the receptor
subtype that is activated as well as the organ/tissue in which the receptor is present. A1
and A3 receptors are coupled to Gi while the A2A and A2B receptors are coupled to Gs. A1
and A2A have a high affinity for adenosine, while the A2B and A3 receptors are considered
to be low affinity. The A1 receptor signals through Gi/o G-proteins and its activation leads
to an inhibition of adenylyl cyclase (AC) which causes a lowering of cyclic AMP
(cAMP) levels. Signaling through the A1 receptor can also lead to activation of IP3/DAG
through the PLC pathway (Tawfik et al., 2005). The A2A receptor signals through the Gs
pathway and its activation leads to stimulation of AC resulting in increased production of
cAMP. Activation of theA2A receptor produces mainly anti-inflammatory effects and this
receptor is involved in coronary vasodilation. The A2B receptor signals through Gs/q and
its activation can either result in increased cAMP or IP3/DAG and Ca2+ levels. Lastly, the
A3 receptor signals through Gi and is negatively coupled to AC.

Asthma
As previously mentioned, adenosine has varied effects. Of particular interest to
this work is the role of adenosine in asthma. Asthma is a chronic lung disease
characterized by inflammation and bronchoconstriction. There is a growing incidence of
asthma in the U.S. such that many experts believe the country is in the midst of an asthma
epidemic. Although there are many treatment options available to manage symptoms,
there is no cure for this disease. Over 20 million people have been diagnosed with
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asthma, with 9 million under the age of 18 years; children are particularly susceptible.
Allergic asthma accounts for about half of these numbers. Several hypotheses have been
put forward to explain the growing asthma epidemic including the hygiene hypothesis
and genetic predisposition.
The disease consists of episodic events which manifest as hyper-responsiveness of
the airways to common triggers like dust, pollen, cold air, cigarette smoke and other
pollutants, resulting in bronchospasm and difficulty in breathing. It can also be induced
by exercise and inhalation of cold air. Airway obstruction occurs due to inflammation,
excessive mucus production, and hyperreactive bronchial smooth muscle. As a
consequence, hypoxemia secondary to hypoventilation is present. Severe acute asthmatic
episodes can be life-threatening and require urgent care. Failure to treat prolonged
respiratory failure can result in death. Initially, the inflammation observed in asthma is
acute in nature but eventually becomes chronic with the progression of the disease, and
long term effects of asthma are linked its inflammatory component. Disease management
consists of anti-inflammatory drugs and bronchodilators.

Adenosine and asthma
Adenosine has long been implicated in the pathogenesis of asthma. Inhalation of
adenosine was shown to be a potent bronchoprovocant in asthmatic patients (Cushley et
al., 1983). This was one of the first studies to demonstrate a role for adenosine in asthma
and it established that guanosine, another purine nucleoside, did not have the same effect.
Inosine, the deaminated adenosine metabolite, did not produce bronchoconstriction
(Mann et al., 1986b), suggesting that the effect on bronchial smooth muscle was specific
to adenosine and possibly involved adenosine receptors. Asthmatic patients also had
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significantly higher levels of adenosine in bronchoalveolar lavage fluid (BAL) and
exhaled breath condensate than normal healthy subjects (Driver et al., 1993; Huszar et al.,
2002). Adenosine can also have indirect effects in the lungs; it causes degranulation of
mast cells which leads to the release of histamine and subsequent cascade of events
including H1-receptor-mediated bronchoconstriction and inflammatory response (Fozard
and Hannon, 2000; Oldenburg and Mustafa, 2005). This mast-cell mediated response is
believed to occur through the A2B receptor although this has not been conclusively
proven (Zhong et al., 2003).
Studies done using mice lacking the ADA enzyme have shown that these mice
have large amounts of adenosine in their lungs and severe lung inflammation (Blackburn
et al., 2000). In fact, these mice were unable to survive beyond three weeks due to
respiratory distress. Further studies using ADA deficient mice demonstrated the presence
of eosinophilia in the lungs and periphery, extensive mast cell degranulation and
increased levels of serum IgE (Zhong et al., 2001). There is evidence that adenosine
causes recruitment of inflammatory cells to the lung (Fan and Mustafa, 2002) and
amplification of the inflammatory response (Spicuzza et al., 2006). Despite all of these
data linking adenosine to asthma, the exact extent of adenosine implication and specific
roles of the four adenosine receptors still have to be delineated.
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Reactive airway diseases and cardiovascular complications
An interesting facet noted in epidemiological studies is that people suffering from
asthma, chronic obstructive pulmonary disease (COPD) and reactive airway diseases are
at an increased risk for developing cardiovascular disease (CVD) (Gan et al., 2004;
Schanen et al., 2005; Sin and Man, 2005). There is an association between atherosclerosis
and stroke with reactive airway diseases. One study found that adult-onset asthma was
associated with increased carotid atherosclerosis in women (Onufrak et al., 2007). Many
studies have shown that impaired lung function is a risk factor for CVD (Tockman et al.,
1995). Bronchial hyperresponsiveness to methacholine is associated with increased
carotid intima-media thickness (Zureik et al., 2004). One of the leading causes for
hospitalizations and deaths occurring in COPD patients is cardiovascular events (Sidney
et al., 2005).
Inflammation is a key event in CVD and several inflammatory mediators and
markers are associated with it, including C-reactive protein (CRP), plasma fibrinogen,
leucocytes, and interleukins (IL-1β, -4, -5, -6, -8 and -13). CRP has been implicated in
atherosclerosis, and levels of this protein are elevated in this condition. The level of CRP
is considered one of the best predictors of the risk of CVD (Yudkin et al., 1999; Pearson
et al., 2003). Interleukins, in particular IL-6 (Yudkin et al., 2000), are also important
markers of CVD.
Recent evidence in animal models indicates that CV complications associated
with asthma are independent of asthma therapy and could be a result of asthma itself.
Myocardial ischemia-reperfusion injury was enhanced in a rabbit model of systemic
allergy and asthma (Hazarika et al., 2004) and allergic inflammation in the airways
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enhanced neutrophil recruitment to the myocardium and severity of ischemia-reperfusion
in a murine model (Hazarika, 2005).
Asthma thus, is a risk factor for cardiovascular disease. However, its potential as
a risk factor in CVD has not been widely studied with respect to mechanisms underlying
the phenomenon, nor have the effects of adenosine been explored on cardiovascular
parameters in asthma. Work done in this dissertation attempts to shed light on both of
these aspects.

Animal models of asthma
The use of animal models has been one of the mainstays for asthma research. Species
including mice, rats, rabbits, guinea pigs, sheep and dogs amongst others have been used
(Abraham et al., 1983; Muccitelli et al., 1987; de Weck et al., 1997; Liu et al., 2005).
There are several advantages and disadvantages in employing animal models to study
asthma. The principle criticism in using animal models of asthma is that none of the
species develop the disease spontaneously nor exhibit the episodic airway hyperresponsiveness of the disease that is characteristic of the human condition, i.e., it is not
possible to reproduce the exact human disease in animals.

The asthma phenotype

generated in animal models is a Th-2 type response with acute inflammation and
increased responsiveness to bronchoprovocants observed. The main advantage to using
animal models is the ability to study intact systems and carrying out in vivo experiments.
Many of these models are also cost effective and a number of species specific probes
have been developed which aid greatly in research. For mechanistic purposes, animal
models are extremely useful and also for drug screening purposes.
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Murine models of asthma
Mice are very commonly used to study asthma, especially for modeling allergic
responses in the airways and lungs. With the increasing number of genetically modified
mice available, these are ideal tools for studying specific aspects of the disease. There
are knock-out mice for all four adenosine receptors as well as mice in which ADA has
been knocked out and double knock-outs with specific adenosine receptors. Mice in
which specific cytokines have been knocked out are also available to study inflammatory
signaling with respect to asthma. These include IL-13 knock out mice which exhibit a
lack of airway remodeling characteristic of asthma (Kumar et al., 2002). One of the main
advantages of using mice to duplicate certain asthmatic features is the ease of various
tools with which allergic models can be developed and also the easy availability and cost
effectiveness of such models. Mice can be sensitized to various antigens including dustmite (O'Brien et al., 1996), (Johnson et al., 2004), ragweed extracts (Oldenburg and
Mustafa, 2005; Fan and Jamal Mustafa, 2006), and one of the more commonly used
allergens, ovalbumin, in a reasonable time frame (Nadeem et al., 2007).
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Purpose and Project Summary
The purpose of this investigation is to understand the effects of asthma beyond the lungs,
specifically to determine if there is any alteration in vascular reactivity. Since adenosine
has major implications in both asthma and on the vasculature, it is important to elucidate
the adenosine-mediated systemic and vascular effects in asthma. Lastly, identifying the
possible adenosine receptor(s) involved in inflammatory and other changes would be able
to provide further insights in understanding the profound and diverse effects of adenosine
in asthma. Determining which receptor is involved in the vascular changes is necessary
for developing potential therapeutic approaches to asthma, particularly with respect to
targeting and reducing the commonly reported adverse vascular effects that are a
consequence with asthma. With this in mind, the following aims were developed:

Aim 1: Identify markers of systemic and local arterial inflammation in an allergic
murine model of asthma.
Hypotheses
(a):

Chronic inflammatory disease of the airway and lung leads to an increase in

systemic levels of several inflammatory mediators including TNF-α, IL-1β, IL-4, and IL13
(b) Chronic inflammatory disease of the airway and lung can lead to local inflammation
of blood vessels (aorta).

11
Aim 2: Characterize the adenosine receptor sub-type(s) involved in altered vascular
response and quantify their expression levels in our model of asthma.
Hypotheses
(a) Multiple adenosine receptors (A1, A2A, A2B, and A3) regulate vascular responses and
are differentially activated in an allergic inflammatory model.
(b) Specific adenosine receptor(s) (A1, A2A, A2B, A3) are either up-regulated or downregulated in asthma

Aim 3: Identify the adenosine receptor subtype(s) involved in vascular inflammation.
Hypothesis: The interaction between inflammatory mediators and adenosine through
specific adenosine receptors is central to a cascade of pro-inflammatory events.
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CHAPTER TWO

MATERIALS AND METHODS

Mice
Balb/c mice, 8-10 weeks old males were obtained from Harlan Sprague Dawley
(Indianapolis, IN). To study vascular effects of A2A receptor-activation, A2A KO and WT
mice were used which were initially obtained from Dr. Catherine Ledent, University of
Brussels, Belgium and maintained as a breeding colony at WVU. Male and female mice
aged 12-14 weeks were used for all A2A adenosine receptor experiments. A1KO mice
were kindly provided by Dr. Stephen Tilley, University of North Carolina, Chapel Hill
and mice aged 8-12 weeks were used for experiments. All mice were kept in community
cages with 12-hr periods of light and dark cycles and were maintained on a ragweed-free
diet with access to water ad libitum. All animal care and experimentation used in this
study were carried out under protocols approved by the Institutional Animal Care and
Use Committee of West Virginia University (Animal Use Protocol # 05-0603 and #061009); animal procedures were monitored by this committee and were done in
accordance with the provisions of the NIH “Guide for the Care and Use of Laboratory
Animals.”

Animal sensitization protocol
Sensitization of mice was performed according to the previously established
protocols including one described from this laboratory (Fan and Mustafa, 2002; Fan et
al., 2003; Oldenburg and Mustafa, 2005; Fan and Mustafa, 2006; Mustafa et al., 2007).
This model of allergic asthma has been shown to develop airway inflammation and
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airway hyper-reactivity to methacholine. In brief, mice were sensitized on days 1 and 6
with i.p. injections of ragweed allergen (Greer Laboratories, Lenoir, NC), 200 µg per
dose, with 200 µL Imject Alum (Pierce Laboratories, Rockford, IL). Non-sensitized
control animals received only the Imject alum with the same volumes. Ten days after
sensitization, the mice were placed in a Plexiglas chamber and challenged with 1%
aerosolized ragweed or with 0.9% saline as a control, using an ultrasonic nebulizer
(DeVilbiss, Somerset, PA) for 20 min both in the morning and afternoon for three
consecutive days. The aerosolization of allergen was performed at a flow rate of 2
mL/min, and the aerosol particles had a median aerodynamic diameter of less 4 µm
(DeVilbiss).
In addition, acute elevations in lung adenosine levels were produced
experimentally by adenosine inhalation (6 mg/ml for 2 min on day 14) in one group of
sensitized-challenged mice and one group of control mice to further enhance allergeninduced effects. This dose was chosen based on previous studies in this model (Fan and
Mustafa, 2002; Fan and Mustafa, 2006). The time frame for experiments was 24-hr postadenosine inhalation, chosen on the basis of an earlier study from this lab which showed
maximum eosinophilic inflammation in airways after 24 hr of adenosine inhalation (Fan
and Jamal Mustafa, 2006), which is a hallmark of asthmatic inflammation. Twenty-four
hours after the last challenge, animals were sacrificed for collection of aorta and blood
for further experiments.
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In-vitro organ bath: For vascular reactivity (aorta)
Preparation of mouse isolated aorta and isometric force measurement
Mice were sacrificed by anesthesia with pentabarbitol sodium (65 mg/kg, i.p.)
followed by thoracotomy and removal of the aorta. This was then carefully cleaned to
remove fat and connective tissue without damaging the tissue and was then cut
transversely into 3-4 mm rings. The rings were mounted vertically between two stainless
steel wire hooks and then suspended in 10 mL organ baths containing Krebs-Henseleit
buffer. The Krebs-Henseleit buffer (pH 7.4) containing 118 mM NaCl, 4.8 mM KCl, 1.2
mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 11 mM glucose and 2.5 mM CaCl2 was
maintained at 37°C with continuous bubbling of 95% O2 and 5% CO2. For measurement
of isometric force response, aortic rings were equilibrated for 90 min with a resting force
of 1g (Tawfik et al., 2005; Ansari et al., 2007b) and change of the bathing solution at 15
min interval. At the end of equilibration period, tissues were contracted twice with 50
mM KCl to determine the contractility of individual aortic rings , which were washed out
with Krebs-Henseleit buffer. Aortic rings were then constricted with phenylephrine (PE,
10-7M) to obtain a steady contraction and changes in tension were monitored
continuously with fixed range precision force transducer (TSD, 125 C, BIOPAC system)
connected to the differential amplifier (DA 100B, BIOPAC system). The data were
recorded using a MP100 digital acquisition system and analyzed using Acknowledge
3.5.7 software (BIOPAC system). After equilibration, the responsiveness and stability of
individual rings were checked by successive administration of a submaximally effective
concentration of PE (10-7 M). The integrity of the vascular endothelium was assessed
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pharmacologically by acetylcholine (ACh; 10-7 M) to produce relaxation of PE precontracted rings. A relaxation of ≥50% with ACh was considered as normal. Aortic rings
were then washed several times with Krebs-Henseleit solution, and allowed to equilibrate
for 30 min before the experimental protocol began in which concentration-responsiveness
to various drugs was measured including NECA (non-selective adenosine analog; 10-11 10-5 M), adenosine (10-11 -10-4 M) and CGS 21860 (selective A2A agonist; 10-11 -10-6 M)
were run parallel in aortic rings. In all cases, the drug was added to yield the next higher
concentration only when the response to the earlier dose reached a steady state. In
experiments where the effects of an antagonist were measured, it was added 30 min
before contraction of the tissue with PE, and was present throughout the experiments.
Contraction/relaxation

responses

were

expressed

as

a

percentage

increase/decrease in the contraction with respect to PE (alone) in response to each
concentration of agonist used.

Airway responsiveness
Airway hyperresponsiveness was measured by whole body plethysmography.
Unrestrained mice were placed in Plexiglass chambers (Buxco Electronics, Wilmington,
NC) and pressure fluctuations during ventilatory cycles were monitored by pressure
transducers. Data was calculated in the form of enhanced pause (Penh) according to a
previously described protocol (Hamelmann et al., 1997).
Penh is a dimensionless index of airway obstruction, and higher the Penh value,
the greater is the obstruction. The waveform (Hamelmann et al., 1997; Drazen et al.,
1999) describing the process of Penh calculation is shown in figure 2.1 and
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mathematically, Penh is obtained by the following equation (Hamelmann et al., 1997;
Drazen et al., 1999).
Penh= PEF/PIF* (TE/Rt-1)
PEF= Peak expiratory height
PIF= Peak inspiratory height
TE= Expiratory time
Rt= Time to expire 65% of the volume
Pause= (TE/RT)-1
Penh= PEF/PIF * Pause
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Figure 2.1: Ventilatory cycle from whole body plethysmography. Te=expiratory time;
Rt= Time to expire 65% of the volume; PEF= Peak expiratory height; PIF= Peak
inspiratory height
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CHAPTER THREE

ADENOSINE-MEDIATED ALTERATION OF VASCULAR REACTIVITY AND
INFLAMMATION IN A MURINE MODEL OF ASTHMA
American Journal of Physiology, May 2008
(Used with permission from Am J Physiol Heart Circ Phsyiol)

Abstract
Chronic respiratory disorders such as asthma are believed to be associated with
adverse cardiovascular events. We hypothesize that asthmatic inflammation translates
into systemic inflammation and alters vascular responses where adenosine (AD) plays an
important role. Therefore, this study investigated the effects of aerosolized AD, used to
elevate lung AD levels, on vascular reactivity and inflammation in our allergic mouse
model of asthma. Balb/c mice were divided into four groups: control (CON), CON +
aerosolized AD (CON + AD), allergen sensitized and challenged (SEN), and SEN +
aerosolized AD (SEN + AD). The animals were sensitized with ragweed (200 µg ip) on
days 1 and 6, followed by 1% ragweed aerosol challenges from days 11 to 13. On day 14,
the CON + AD and SEN + AD groups received a single AD aerosol challenge (6 mg/ml)
for 2 min, followed by the collection of the aorta and plasma on day 15. Organ bath
experiments showed concentration-dependent aortic relaxations to AD in the CON and
CON+ AD groups, which were impaired in the SEN and SEN + AD groups. Real-time
PCR data showed changes in aortic AD receptors (ARs), with the expression of A1ARs
up-regulated, whereas the expression of A2ARs and endothelial nitric oxide synthase
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genes were down-regulated, resulting in an impairment of vasorelaxation in the SEN and
SEN + AD groups. The A1AR antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX)
reversed the impairment in vasorelaxation observed in the SEN and SEN + AD groups,
whereas the A2BAR antagonist alloxazine inhibited vasorelaxation in all groups. Allergen
challenge caused systemic inflammation in allergic mice, with AD aerosol further
enhancing it as determined by the inflammatory cytokines profile in plasma. In
conclusion, asthmatic mice showed altered vascular reactivity and systemic inflammation,
with AD aerosol further exacerbating these effects.

Introduction
Asthma, a chronic disease affecting 10% of the population in North America, is
characterized by perpetuation and amplification of inflammation in the airways and
systemic circulation (Busse and Lemanske, 2001; Braman, 2006). Over the past two
decades, adenosine has been increasingly implicated in the pathophysiology of asthma.
Chronic cellular stress, inflammation and tissue damage observed in asthmatic airways
are associated with increases in adenosine levels (Driver et al., 1993). The inhalation of
adenosine leads to bronchoconstriction in asthmatics as opposed to normal subjects who
show no response to adenosine (Cushley et al., 1984). The elevation in lung adenosine
levels observed in adenosine deaminase (ADA)-deficient mice lead to severe pulmonary
inflammation, airway hyper-reactivity and airway remodeling (Chunn et al., 2001;
Blackburn and Kellems, 2005), suggesting that a chronic elevation of adenosine levels
can lead to the promotion of lung inflammation.
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Several epidemiological studies have reported that people suffering from chronic
respiratory diseases such as asthma are at an increased risk for developing cardiovascular
complications (Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et al., 2004;
Knoflach et al., 2005). Systemic inflammation in these patients is believed to be a
consequence of airway inflammation (Jousilahti et al., 2002; Nadeem et al., 2003), which
may be one of the reasons for altered cardiovascular parameters in these patients. Some
recent studies have also reported enhanced systemic inflammation, myocardial ischemiareperfusion injury and neutrophil recruitment to the myocardium in animal models of
allergic asthma (Hazarika et al., 2004, 2007). However, no study so far has attempted to
establish a link between airway inflammation, vascular reactivity and systemic
inflammation, especially in relation to adenosine.
Adenosine has a well established role in the control of vascular tone, and its
effects are exerted through the activation of the four different adenosine receptor (AR)
subtypes: A1, A2A, A2B, and A3 (Tabrizchi and Bedi, 2001). A1 and A3 ARs have been
shown be involved in vasoconstriction (Shepherd et al., 1996; Talukder et al., 2002b;
Hansen et al., 2003; Tawfik et al., 2005) whereas A2A and A2B ARs cause vasorelaxation
of aorta (Lewis et al., 1994; Grbovic and Radenkovic, 2003; Ansari et al., 2007b).
However, the modulation of aortic ARs expression in response to allergen and adenosine
aerosol challenge as an added insult in a murine model of asthma has not been previously
studied.
Allergen has been shown to cause the release of adenosine among other
inflammatory mediators from allergic lung and activated leukocytes (Mann et al., 1986b;
Mann et al., 1986a). Adenosine generated in allergic lungs may be involved in the release
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of further chemotactic and inflammatory mediators in the lung and systemic circulation
by acting on its receptors present on different cells including mast cells, eosinophils,
neutrophils and other inflammatory cells (Driver et al., 1991; Fan and Jamal Mustafa,
2006; Nadeem and Mustafa, 2006; Spicuzza et al., 2006). This has been confirmed by
recent observations where experimentally induced temporary elevations in lung
adenosine levels through the inhalation of adenosine (resulting from breakdown of
adenosine 5'-monophosphate) have been shown to cause an increase in infiltration of
eosinophils in patients with asthma (van den Berge et al., 2004). A recent study from our
lab has also shown increased release of inflammatory cell markers in the lung and plasma
after inhalation of adenosine aerosol in allergic mice (Fan and Mustafa, 2002). These
studies thus suggest that adenosine inhalation amplifies allergen-induced airway
inflammation in the lungs.
Therefore, this study was undertaken to investigate the effects of inhaled
adenosine on vascular reactivity and systemic inflammation using our murine model of
asthma. Our data suggest that asthmatic mice have altered peripheral vascular reactivity
and systemic inflammation, with inhaled adenosine further exacerbating these effects.

Materials and Methods
Animals: Balb/c mice, 8-10-wk-old males, were obtained from Harlan Sprague
Dawley (Indianapolis, IN). The animals were maintained on a ragweed-free diet. All
experimental animals used in this study were under a protocol approved by the
Institutional Animal Care and Use Committee of West Virginia University.
Animal sensitization: Sensitization was performed according to the protocol described
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earlier from this laboratory (Fan and Mustafa, 2002; Fan et al., 2003; Oldenburg and
Mustafa, 2005; Fan and Jamal Mustafa, 2006; Mustafa et al., 2007). This model of
allergic asthma has been shown to develop airway inflammation and airway hyperreactivity to methacholine. The study comprised of four groups of animals: 1) Control
(CON), 2) Control challenged with 6 mg/ml of adenosine aerosol for 2 min on day 14
(CON + AD), 3) allergen sensitized and challenged (SEN), and 4) allergen sensitized and
challenged further challenged with 6 mg/ml of adenosine aerosol for 2 min on day 14
(SEN + AD). Mice were sensitized on days 1 and 6 with i.p. injections of ragweed
allergen (Greer Laboratories, Lenoir, NC), 200 µg per dose with 200 µL Imject Alum
(Pierce Laboratories, Rockford, IL). Non-sensitized control animals received only the
Imject alum with the same volumes. Ten days after sensitization, the mice were placed in
a Plexiglas chamber and challenged with 1% aerosolized ragweed or with 0.9% saline as
a control, using an ultrasonic nebulizer (DeVilbiss Somerset, PA) for 20 min both in the
morning and afternoon for three consecutive days. The aerosolization of allergen was
performed at a flow rate of 2 mL/min, and the aerosol particles had a median
aerodynamic diameter of less 4 µm (De Vilbiss).
Acute elevations in lung adenosine levels were produced experimentally by
adenosine inhalation (6 mg/ml for 2 min on day 14) to SEN+AD group to further enhance
allergen-induced effects (the control for this group was CON+AD). This dose was chosen
based on our previous studies in this model (Fan and Mustafa, 2002; Fan and Jamal
Mustafa, 2006). Adenosine inhalation in this model has been shown to enhance allergeninduced airway inflammation and airway hyper-reactivity to adenosine (or its analog
NECA) (Fan and Mustafa, 2002; Fan et al., 2003; Fan and Jamal Mustafa, 2006). ADA-
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deficient mice having sustained and chronic elevations in lung adenosine levels have also
been shown to have similar features (Chunn et al., 2001). We chose 24-h post adenosine
inhalation for our current studies based on an earlier study from our lab which showed
maximum eosinophilic inflammation in airways after 24 h of adenosine inhalation (Fan
and Jamal Mustafa, 2006), which is a hallmark of asthmatic inflammation. CON and SEN
groups received only saline on day 14. Twenty-four hr after the last challenge, animals
were sacrificed for collection of aorta and blood for further experiments.

Preparation of isolated mouse aorta and isometric force measurement
Mice were euthanized by anesthesia with pentabarbitol sodium (65 mg/kg ip) followed by
thoracotomy and the removal of the aorta, which was then cut transversely into 3 to 4-mm
rings. The rings were mounted vertically between two stainless steel wire hooks and then
suspended in 10-ml organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit
buffer (pH 7.4), containing (in mM) 118 NaCl, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25
NaHCO3, 11 glucose, and 2.5 CaCl2, was maintained at 37°C with continuous bubbling
of 95% O2-5% CO2. For the measurement of isometric force response, the aortic rings
were equilibrated for 90 min with a resting force of 1 g and a change of the bathing
solution at 15-min intervals. The resting force of 1 g has been used earlier in our
laboratory (Tawfik et al., 2005; Ansari et al., 2007b). At the end of the equilibration
period, the tissues were contracted with 50 mM KCl to check the contractility of
individual aortic rings twice, which were washed out with Krebs-Henseleit buffer. The
aortic rings were then constricted with phenylephrine (PE; 10–7 M) to obtain a steady
contraction, and changes in tension were monitored continuously with a fixed-range
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precision force transducer (TSD 125C; Biopac) connected to a differential amplifier (DA
100B; Biopac). The data were recorded using the MP100 Biopac digital acquisition
system and analyzed using Acknowledge 3.5.7 software (Biopac).

Contraction/relaxation experiments
After equilibration, the responsiveness and stability of individual rings were checked by
successive administration of a submaximally effective concentration of PE (10–7 M). The
integrity of the vascular endothelium was assessed pharmacologically by acetylcholine
(10–7 M) to produce the relaxation of PE-precontracted rings. The aortic rings were then
washed several times with Krebs-Henseleit solution and allowed to equilibrate for 30 min
before the experimental protocol began.

Experimental protocol
The concentration-response curves (CRCs) for adenosine (10–11–10–4 M) were run in
parallel in aortic rings from all the groups. In all cases, adenosine was added to yield the
next higher concentration only when the response to the earlier dose reached a steady
state. In experiments where the effects of an antagonist were measured, it was added 30
min before the contraction of the tissue with PE and was present throughout the
experiments.

Real time PCR: A1, A2A, A2B, A3 AR and eNOS genes expression
The aortic tissues from all experimental groups were processed for total RNA isolation
using the TRIzol reagent from Life Technologies/Invitrogen, followed by DNase
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treatment to eliminate potential genomic DNA contamination as described recently by our
laboratory (Ansari et al., 2007b). This was followed by a conversion of 0.5 µg of total
RNA into cDNA using a high-capacity cDNA archive kit (Applied Biosystems, Foster
City, CA) in a total volume of 100 µl. Real-time PCR was then performed using an ABI
PRISM 7300 detection system (Applied Biosystems) using Taqman Universal Mastermix
(Applied Biosystems, Branchburg, NJ) according to the instructions of the manufacturer.
The reaction volume (25 µl) consisted of (in µl) 12.5 2x Taqman Universal Mastermix, 1
cDNA, and 1.25 20x 6-carboxy-fluorescein-labeled Taqman gene expression assay master
mix solution. For the real-time PCR of the concerned genes [A1-, A2A-, A2B-, and A3AR
and endothelial nitric oxide synthase (eNOS)], the Taqman inventoried assays-on-demand
gene expression products (assay identifications for A3-, A2B-, A2A-, and A1AR and eNOS,
respectively,

are

Mm00802076_m1,

Mm00839292_m1,

Mm00802075_m1,

Mm01308023_m1, and Mm00435204_m1) were purchased from Applied Biosystems.
18S ribosomal RNA was used as an endogenous control. The fold difference in the
expression of target cDNA was determined using the comparative cycle threshold method
as described earlier (Livak and Schmittgen, 2001).

Assessment of systemic inflammation
Mice were euthanized by pentobarbitone sodium (65 mg/mL, i.p.), followed by collection
of blood by cardiac puncture in heparinized syringes. The blood collected from different
groups was centrifuged at 800 g for 10 min at 4° C and the resulting plasma was used for
cytokine and C-reactive protein (CRP) assays.
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Multiplex cytokine assay: Multiplex cytokine assay of IL-1α, IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-9, IL-10, IL-12 (p70), , IL-13, IL-15, IL-17, TNFα, IFNγ, GMCSF, MIP1α, MCP-1, KC, RANTES, IP-10, G-CSF in the plasma was measured by a commercial
kit from Linco Research (St. Charles, Missouri) using the Luminex 200 system (Luminex
Corp., Austin, Tx), which is a multianalyte bioassay detection system capable of
performing up to 100 assays simultaneously in a single microtiter plate well. This system
uses polystyrene microspheres internally dyed with red and infrared fluorophores that can
be individually identified. The fluorescent microspheres were coated with capturing
antibodies specific for different chemokines. The chemokine-captured beads after
incubation with the sample were then mixed with phycoerythrin-conjugated detection
antibodies to form immune complexes. Following incubation, washing and acquisition of
fluorescence data, the concentration results were generated in graphical format using the
standard curve generated for each cytokine. Results were expressed in pg/mL.
C-reactive protein assay: C-reactive protein was measured in plasma with a mouse
high-sensitive ELISA kit according to the instruction manual (Kamiya Biomedical
Company, Seattle, WA). This kit specifically detects mouse CRP. Results were expressed
in ng/mL.

Drugs used
Acetylcholine, adenosine and phenylephrine were dissolved in distilled water. 1,3dipropyl-8-cyclopentylxanthine (DPCPX) and 2, 4-dioxobenzo[g] pteridine (alloxazine)
were dissolved in 100% DMSO as a 10 mM stock solution. The final concentration of
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DMSO in the organ bath which had a total volume of 10 mL, had no effect by itself on
the aortic rings (Ansari et al., 2007b). Unless stated otherwise, all chemicals were of the
highest grade available and were purchased from Sigma Chemicals (St. Louis, MO).

Statistical Analysis
The data were expressed as mean± SEM. Comparisons among different groups were
analyzed by ANOVA (analysis of variance) followed by Tukey’s multiple comparison
test/Bonferroni’s selected pair test. Comparison between two groups was assessed by
unpaired t-test. A p value of less than 0.05 was considered as the level of significance for
all statistical tests. All the statistical analyses were performed using the Graph Pad Prism
statistical package.

Results
Systemic inflammation in control, allergic and adenosine aerosolized allergic mice
Table 3.1 shows the multiplex cytokine profile in all the groups. Allergen challenge
significantly increased plasma levels of inflammatory cytokines IL-5, IL-6, IL-13, and
MCP-1 in sensitized (SEN) compared with control (CON) mice. Allergen-sensitized and
challenged mice exposed to adenosine aerosol (SEN + AD) had the highest level of the
pro-inflammatory cytokines including IL-1β, IL-5, IL-13, MCP-1, MIP-1α and TNF-α
compared to other groups. Other cytokines in the panel were either undetectable or not
different among the groups (data not shown). In addition, the cytokine profile was also
studied in the CON + AD group. Cytokine levels were not different between this group of
animals aerosolized with adenosine compared with the CON group, suggesting that
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aerosolized adenosine in the absence of allergic inflammation had no effect on the
inflammatory cytokine profile. CRP was also measured as an important systemic
inflammatory marker. Plasma CRP levels significantly increased in the SEN compared
with the CON group, with a further increase in the SEN + AD compared with the SEN
group. Again, there was no difference between the CON and CON + AD groups in CRP
levels. These data show that sensitized mice challenged with allergen have systemic
inflammation and that aerosolized adenosine further enhances the inflammation in these
mice. Earlier studies from our laboratory have also shown no difference in the lung
inflammation of control mice aerosolized with adenosine (Fan and Mustafa, 2002; Fan
and Jamal Mustafa, 2006).

Vascular reactivity in control, allergic and allergic + adenosine groups
The aortic relaxation/contraction responses to adenosine were studied in each of the
following four groups: CON, CON + AD, SEN, and SEN + AD. Organ bath data showed
a concentration-dependent relaxation response to adenosine in the CON aorta (Fig. 3.1).
The maximum relaxation produced by adenosine (10–4 M) was 21% and 25% in the CON
and CON + AD groups, respectively. There was no difference in the vasorelaxation
between the CON and CON + AD groups. Adenosine-induced aortic relaxations were
impaired in the SEN aorta with a maximum relaxation of 7%. The impairment of
vasorelaxation response to adenosine observed in the SEN group was further aggravated
in the SEN + AD aorta. Adenosine failed to elicit any relaxation response in the SEN +
AD group; however, it produced a contractile response (–5%) at higher doses. These data
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show that allergen sensitization and challenge altered the vascular reactivity, with
adenosine aerosol further exacerbating it in allergic mice.

Endothelial function and eNOS expression in control, allergic and allergic +
adenosine groups
The SEN and SEN + AD groups had significantly lower (~50% relaxation) endothelial
response to acetylcholine (Fig 3.2A) compared with that of the respective controls (~75%
relaxation). Real-time PCR data also showed that the expression of eNOS in the aorta was
significantly decreased in the SEN and SEN + AD groups compared with the Con group
(Fig 3.2B). These data show that allergen challenge probably led to dysfunctional
endothelium in the SEN and SEN + AD groups.
With the aerosolization of adenosine, it is difficult to assess the exact amount of
adenosine reaching the lungs. However, the dose we have chosen is based on previous
work from our laboratory (Fan and Mustafa, 2002; Fan et al., 2003; Fan and Jamal
Mustafa, 2006). This dose of adenosine (6 mg/ml) has no systemic effects, which has
been shown by the lack of any systemic inflammation, improvement in vascular
reactivity, and endothelial response in the CON + AD compared with the CON group. We
also know that the half-life for adenosine is less than a minute. In fact, this was the reason
why adenosine was chosen and not an adenosine analog. Most of the systemic effects of
this dose would be gone within minutes. Therefore, it is unlikely that the effects of
adenosine in this study are due to any hemodynamic changes in these animals.
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Adenosine receptors gene expression in control, allergic and allergic + adenosine
groups
To gain further insight into the pattern of the expression of ARs and their involvement in
the impairment of vasorelaxation observed in the SEN and SEN + AD groups, we first
measured the aortic gene expression of all ARs before conducting organ bath
experiments. Real-time PCR data showed that A1 (Fig 3.3A), A2A (Fig 3.3B) and A2BAR
(Fig 3.3C) expression was decreased in the SEN compared with the CON group, whereas
A3AR expression remained unaffected (data not shown). The expression of A1AR
increased significantly in the SEN + AD compared with the SEN group, whereas A2Aand A2BARs decreased further; however, only the decrease in A2BAR expression reached
statistical significance. These data show that an alteration in AR expression is responsible
for the impairment of vasorelaxation observed in the SEN and SEN + AD groups.

Effect of specific A1 AR (DPCPX) and A2B AR (alloxazine) antagonists on vascular
reactivity in control, allergic and allergic + adenosine groups
Based on real-time PCR data, we used the A1AR antagonist to reverse the impairment
observed in the SEN and SEN + AD groups since A1AR activation has been shown to
cause vasoconstriction in earlier studies from our laboratory (Tawfik et al., 2005).
Treatment of the aorta with the A1AR antagonist DPCPX (10–5 M) before concentrationresponse with adenosine resulted in a reversal of impaired vasorelaxation in the SEN and
SEN + AD groups (Fig 3.4). DPCPX shifted the CRC to adenosine toward the left in the
SEN and SEN + AD groups, with the vasorelaxation observed in these groups being
similar to the CON group (Fig 3.1). A concentration-dependent relaxation was seen in
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CON animals (CON and CON + AD), which was not affected by DPCPX except at the
highest concentration of adenosine that was significant (data not shown).
We expected the inhibition of vasorelaxation by the blocking of A2BAR since it is
considered to be involved in the relaxation of the aorta (Grbovic and Radenkovic, 2003;
Ansari et al., 2007b). The pretreatment of the aorta with the A2BAR antagonist alloxazine
(10–4 M) before CRC with adenosine resulted in the inhibition of vasorelaxation observed
in the CON and CON + AD aorta. Alloxazine shifted the CRC to adenosine toward the
right, indicating a contraction in the CON and CON + AD aorta (Fig 3.5A). Impaired
vasorelaxation observed in the SEN and SEN + AD groups was also affected by prior
treatment of the aorta with alloxazine (Fig 3.5B), with a further rightward shift of their
respective CRCs. These data suggest that A1- and A2BARs have a significant role in the
impairment of vascular reactivity observed in the SEN and SEN + AD groups. DPCPX
and alloxazine are selective inhibitors of A1- and A2BAR, respectively, and have been
used by others and our laboratory in earlier studies (Rose Meyer et al., 2003; Tawfik et
al., 2005; Ansari et al., 2007b).
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Table 3.1: Systemic inflammation as assessed by levels of inflammatory cytokines in
plasma of control (CON), adenosine aerosolized control (CON+AD), allergic (SEN)
and adenosine aerosolized allergic (SEN+AD) mice; Values are expressed as mean ±
SEM (n=5-8).

Inflammatory
marker

CON

CON+AD

SEN

SEN+AD

IL-1β (pg/ml)

3.46±0.21

3.29±0.09

3.2±0.06

24.08±10.32$#

IL-5 (pg/ml)

3.35±0.14

4.19±0.67

8.22±1.65$

11.12±1.50$

IL-6 (pg/ml)

10.42±2.754

12.90±3.79

60.47±17.63$

43.85±10.08$

IL-13 (pg/ml)

27.44±5.57

33.19±7.60

45.41±9.91$

170.5±49.97$#

MCP-1 (pg/ml)

37.26±4.80

39.91±4.59

56.48±7.26$

119.6±29.01$#

MIP-1α (pg/ml)

51.06±4.69

54.36±8.13

53.38±12.47

165.0±31.57$#

TNFα (pg/ml)

6.66±1.03

5.52±0.360

6.25±0.230

14.22±3.60$#

C-reactive

13.75±0.69

14.51± 0.67

18.18±1.83$

24.42±2.42$#

protein (ng/ml)

$

p<0.05 as compared to CON; #p<0.05 as compared to SEN
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Figure 3.1 Concentration-response curves for adenosine mediated relaxation/contraction
in control (CON), adenosine aerosolized control (CON+AD), allergic (SEN) and
adenosine aerosolized allergic (SEN+AD) mice. Values are expressed as mean ± SEM
(n=8). On the ordinate, positive and negative values indicate relaxation and contraction,
respectively. *P<0.05 as compared to CON/CON+AD; # P<0.05 as compared to SEN.
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Figure 3.2 Endothelial responses to ACh in control (CON), adenosine aerosolized
control (CON+AD), allergic (SEN) and adenosine aerosolized allergic (SEN+AD) mice.
(A) Effect of acetylcholine (10-7 M) on phenylephrine (PE) precontracted aorta (n=8); (B)
Expression of eNOS by real time PCR (n=4). For gene expression by comparative CT
method using real time PCR, the CON group was used as the calibrator against which all
other groups were compared. Values are expressed as mean ± SEM. *P<0.05 as compared
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Figure 3.3 Expression of (A) A1, (B) A2A, and (C) A2B adenosine receptors by real time
PCR in mice aorta of control (CON), allergic (SEN) and adenosine aerosolized allergic
(SEN+AD) mice. For gene expression by comparative CT method using real time PCR,
the CON group was used as the calibrator against which all other groups were compared.
Values are expressed as mean ± SEM (n=4). *P<0.05 as compared to CON; #P<0.05 as
compared to SEN.
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Figure 3.4 Effect of a specific A1 AR antagonist, DPCPX (10-5 M) on adenosinemediated relaxation/contraction in aorta of allergic (SEN) and adenosine aerosolized
allergic (SEN+AD) mice. Values are expressed as mean ± SEM (n=8). On Y-axis,
positive and negative values indicate relaxation and contraction respectively. *P<0.05 as
compared to SEN/SEN+AD.
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Figure 3.5 Effect of A2B AR antagonist, Alloxazine (10-4 M) on adenosine-mediated
relaxation/contraction in aorta of (A) control mice (CON); and (B) allergic (SEN) and
adenosine aerosolized allergic (SEN+AD) mice. Values are expressed as mean ± SEM
(n=4-8). On Y-axis, positive and negative values indicate relaxation and contraction
*

respectively.

P<0.05 as compared to CON/CON+AD; #P<0.05 as compared to
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Discussion
The principal finding of the present study is that allergic mice had impaired
vasorelaxation to adenosine and systemic inflammation, both of which were further
aggravated after acute adenosine aerosol challenge in these mice. The AR expression
profile was also altered in allergic mice and those aerosolized with adenosine after
allergen challenge, which resulted in an impairment of vasorelaxation in these mice.
Endothelium was found to be dysfunctional in both of these groups, since they had a
decrease in aortic eNOS expression and endothelial relaxation to acetylcholine. The
A1AR antagonist DPCPX attenuated the impairment in vasorelaxation observed in
allergic mice and those subjected to adenosine aerosol after allergen challenge, whereas
the A2BAR antagonist alloxazine impaired the vasorelaxation further in these groups,
supporting a role for A2BAR in aortic relaxation.
Airway inflammation is associated with chronic elevations in lung adenosine
levels that may be due to the release of adenosine among other inflammatory mediators
from sensitized lung and activated leukocytes (Mann et al., 1986b; Mann et al., 1986a;
Driver et al., 1993). This is also experimentally supported by chronically increasing lung
adenosine levels by knocking out ADA, an enzyme responsible for adenosine breakdown
or temporarily by the inhalation of adenosine aerosol, as in this study. Mice deficient in
the ADA enzyme develop severe pulmonary inflammation, airway hyperreactivity, and
airway remodeling in association with the elevated levels of adenosine in the lungs
(Chunn et al., 2001; Blackburn and Kellems, 2005). Adenosine inhalation to the allergic
lungs has also been shown to increase further airway responsiveness and inflammatory
mediators (Driver et al., 1991; Fan and Mustafa, 2002; van den Berge et al., 2004; Fan

39
and Jamal Mustafa, 2006), suggesting an important role for adenosine in the amplification
of lung inflammation.
Systemic inflammation has also been reported earlier in humans with asthma and
animal models of asthma (Jousilahti et al., 2002; Hazarika et al., 2004). Hazarika et al
(Hazarika et al., 2007) recently showed an increase in neutrophils and eosinophils in the
bronchoalveolar lavage and blood in a murine model of asthma. Systemic inflammatory
markers have also been shown to be elevated in patients with asthma and in the allergic
mouse model of asthma after the adenosine aerosol challenge performed earlier by our
laboratory (Driver et al., 1991; Fan and Jamal Mustafa, 2006). We further extended these
observations in the present study to investigate the cytokine profile in systemic
circulation in our murine model of asthma. We found that allergic mice exposed to acute
adenosine aerosol had increased systemic inflammation since several pro-inflammatory
cytokines levels (IL-1β, IL-5, IL-13, MCP-1, MIP-1α and TNF-α) were found to be the
highest in this group. A recent report from this laboratory using this model of asthma has
also shown increased activities of eosinophilic peroxidase, myeloperoxidase and βhexosaminidase not only in the lung but also in the systemic circulation of allergic mice
exposed to adenosine aerosol (Fan and Jamal Mustafa, 2006). Adenosine aerosol in
humans with asthma has also been shown to cause increased release of neutrophil
chemotactic factor in serum (Driver et al., 1991). These studies suggest that adenosine
enhances the release of systemic inflammatory mediators from sensitized inflammatory
cells. Our murine model of asthma, therefore, was appropriate to study the inflammatory
effects of adenosine in combination with allergen on vascular reactivity.
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Asthma has been associated with an increased incidence of cardiovascular
disorders (Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et al., 2004;
Knoflach et al., 2005); however, there is little information regarding the role of asthmatic
inflammation in the development of cardiovascular disease, especially in relation to the
vascular effects of adenosine. In the present study, adenosine produced a concentrationdependent vasorelaxation in control mice, which was impaired in allergic mice. Vascular
reactivity to adenosine was further altered in aorta of allergic mice that had received
aerosolized adenosine. These data implicated a role for ARs in impairment of the
vasorelaxation response in allergic mice and those challenged with adenosine aerosol
after allergen. We have found that allergic animals subjected to theophylline inhalation
before adenosine aerosol challenge had improved aortic vasorelaxation to the nonselective adenosine analog 5'-N-ethylcarboxamidoadenosine (NECA; unpublished data).
This further supports a role for adenosine in impaired vasorelaxation.
As the direct effects of adenosine on hemodynamic parameters (blood pressure,
oxygen saturations, and heart rate) were not assessed, it is possible that there could be
adenosine-mediated effects on vasculature independent of inflammation in the allergic
group (SEN + AD). The exact cause of why adenosine inhalation blunted aortic
vasorelaxation to adenosine in sensitized and challenged mice, but not in control mice, is
unclear. However, because the CON + AD group did not show a change in inflammatory
markers and vasorelaxation to adenosine, it is likely that changes observed in the
vasculature were due to allergen and adenosine in sensitized mice. Further studies are
needed to completely assess the effects of adenosine on hemodynamic parameters in this
model of asthma.
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To gain further insight into the AR responsible for the alteration in vascular
reactivity, changes in ARs expression in allergen and adenosine-aerosolized allergic mice
were measured. Real time PCR data showed a down-regulation of A1, A2A and A2B ARs
in allergen-sensitized and challenged mice, the net result possibly being the impaired
vasorelaxation observed in this group since it is known that A2A AR and A2B AR are
involved in vasorelaxation (Grbovic and Radenkovic, 2003; Ansari et al., 2007b). A2A
and A2B ARs expression decreased further and the A1 AR expression increased in allergic
mice exposed to adenosine aerosol compared with allergic mice, leading to aortic
contraction in this group. This effect could be due to the combined net result of an
increase in the A1 AR and further decrease in the expression of A2 ARs since the former
is involved in vasoconstriction and latter in vasorelaxation, as shown in earlier studies
from others and our laboratory (Lewis et al., 1994; Tawfik et al., 2005; Ansari et al.,
2007b).
Real-time PCR studies of ARs prompted us to look further into the roles of A1 AR
and A2B AR on vascular responses. The A2B AR antagonist alloxazine blocked the
vasorelaxation in controls and caused a further impairment in allergic mice and those
exposed to adenosine aerosol after allergen challenge, suggesting that adenosinemediated vasorelaxation could mainly be via the A2B AR. The A1 AR antagonist DPCPX
reversed the impaired vasorelaxation in allergic mice and those exposed to adenosine
aerosol after allergen challenge, suggesting that the A1 AR has an important role in
vasoconstriction, especially when the vasorelaxant A2B AR is downregulated. In an
unpublished observation from our lab, pretreatment of aorta with the selective A2A
antagonist, SCH 58261, showed a decrease in NECA-induced aortic relaxation in control
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mice. However, SCH 58261 pretreatment did not have any significant effect on altered
aortic relaxation to NECA observed in SEN and SEN + AD groups, suggesting a limited
role in vascular reactivity for the A2A AR in this particular experimental model. In
conclusion, the data further support the involvement of A1 AR in contraction and A2B AR
in relaxation of mice aorta in our model of allergic asthma.
The endothelium serves as an important regulator of vascular function and
homeostasis by releasing mediators such as nitric oxide and prostaglandins (Mombouli
and Vanhoutte, 1999); however, its role in relation to allergen exposure and adenosine
challenge has not been explored. Allergen exposure probably contributed to the
impairment in endothelial responses observed in allergic and adenosine aerosolized
allergic mice since eNOS expression and vasorelaxation to acetylcholine was decreased
equally in both of these groups. The exact cause of this dysfunction is not known but it
could be possibly due to an increase in systemic inflammatory cytokines as they are
reported to suppress eNOS and nitric oxide production (Cardaropoli et al., 2003; Li et al.,
2004).
Endothelial dysfunction has been reported earlier after exposure to particulate
matter in aorta of mice (Cozzi et al., 2006). Nurkiewicz et al (Nurkiewicz et al., 2004)
have also shown impairment of endothelium-dependent arteriolar dilation in rat
spinotrapezius muscle upon inhalation of particulate matter. Endothelial dysfunction
caused by allergen exposure could be somewhat similar to that of particulate matter
exposure in many ways. First, allergen particle size is in the same range as that of
particulate matter. Second, particulate matter is known to cause lung inflammation, which
spills over in systemic circulation, leading to endothelial dysfunction and other
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cardiovascular complications (Nurkiewicz et al., 2006; Bai et al., 2007). It is also
reported to be associated with pulmonary as well as cardiovascular disorders (Schwarze
et al., 2006).
The fact that endothelial responses to acetylcholine and eNOS expression were
almost equal in allergic mice and those exposed to adenosine aerosol after allergen
challenge, whereas vasorelaxation responses to adenosine were different between these
groups, could be due to two reasons. First, it could be due to the further increase in
several pro-inflammatory cytokines found in allergic mice exposed to adenosine aerosol
as some of these cytokines are reported to directly alter vascular function (Tousoulis et
al., 2006). Second, it could be due to the increased A1AR and decreased A2B AR
expression favoring aortic contraction in allergic mice exposed to adenosine aerosol.
Further studies are required to delineate the role of each AR in alteration of vascular
responses using specific AR knock-out mice.
In conclusion, our findings provide evidence for the first time that there are
alterations in systemic parameters (inflammation, lower endothelial response and
impaired vasorelaxation to adenosine) as a result of allergen exposure and adenosine
aerosol challenge in sensitized mice. Therefore, therapeutic strategies designed to
attenuate lung inflammation should also focus on the prevention of systemic
inflammation and harmful systemic side effects. This strategy may be beneficial in
lowering the incidence of adverse cardiovascular events in asthmatics.
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CHAPTER FOUR

ROLE OF A2A ADENOSINE RECEPTORS IN THE REGULATION OF
VASCULAR TONE

Abstract
Adenosine mediates vascular responses through its 4 receptor subtypes: A1, A2A,
A2B and A3. In the murine aorta, the A2B receptor is believed to contribute to
vasorelaxation while the role of the A2A receptors is not well documented. The current
study was undertaken to investigate the role of A2A receptors on aortic tone using A2A
adenosine receptor knock-out (A2AKO) and corresponding wild-type (A2AWT) mice for
experiments along with suitable pharmacological tools. Experiments included organ bath
studies and real time RT-PCR for adenosine receptor (AR) gene expression studies.
Isolated aortic rings prepared from A2AWT and A2AKO mice were precontracted with
phenylephrine (10-7M) and concentration-response curves for adenosine analogs and
selective agonists/antagonists were obtained. NECA (non-selective adenosine analog;
EC50 = 6.78µM) and CGS 21680 (A2AAR selective agonist; EC50 = 0.013µM) produced
concentration-dependent relaxation (25% and 28% relaxation with NECA at 10-5M and
CGS 21860 at 10-5M, respectively) in A2AWT aorta. In A2AKO aorta, NECA (EC50 =
0.075µM) induced concentration-dependent contraction (47% at 10-6M; p<0.05 compared
to A2AWT) while CGS 21860 produced no response. SCH 58261 (10-6 M; A2AAR
selective antagonist) abolished vasorelaxation in A2AWT (p<0.05) while no change was
observed in A2AKO. When DPCPX (10-5 M; A1 selective antagonist) was used, greater
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vasorelaxation was observed in A2AWT (50% vs. 25% in controls; p<0.05) while A2AKO
showed less contraction (5% vs. 47% in controls; p<0.05). Aortic endothelial function,
determined by the response to acetylcholine, was significantly greater in WT compared to
KO (66% in WT vs. 51% in KO; p<0.05). In conclusion, A2AAR KO mice had
significantly lower aortic relaxation and endothelial function, suggesting that the A2AAR
plays an important role in vasorelaxation, probably with the endothelium playing a role.

Introduction
Adenosine is a ubiquitous endogenous nucleoside that has several physiological
effects which are mediated through the four adenosine receptor (AR) subtypes, i.e., A1,
A2A, A2B and A3. Adenosine is known to modulate cardiac effects (Shryock and
Belardinelli, 1997) and vascular responses. A1 receptors are involved in lowering the
heart rate (Evans et al., 1982; Belardinelli et al., 1989) and have a negative role in
regulating blood pressure (Brown et al., 2006). All four receptors are involved in the
regulation of vascular responses (Tabrizchi and Bedi, 2001). The vascular effects of
adenosine differ according to the receptor subtype activated, the type of vascular bed
involved and the species.
A1 and A3 ARs have been shown to be involved in vasoconstriction (Shepherd et
al., 1996; Talukder et al., 2002b; Hansen et al., 2003; Tawfik et al., 2005) whereas A2A
and A2B ARs cause vasorelaxation (Lewis et al., 1994; Grbovic and Radenkovic, 2003;
Ansari et al., 2007b). The A2AAR was found to play a major role in the mediation of
coronary vasodilation caused by adenosine and adenosine agonists (Belardinelli et al.,
1998). In rat kidneys, the vasoconstrictor response is mediated via the activation of A1

46
receptors (Rossi et al., 1988) and both A2A and A2B receptors are present in renal
microvasculature, contributing differentially to vasodilation (Tang et al., 1999). In the
pulmonary circulation, findings suggest that adenosine induced relaxation is mediated via
the A2B receptor via a nitric oxide independent mechanism (Haynes et al., 1995). It has
been found that in mice, adenosine-induced aortic relaxation is predominantly mediated
via A2B adenosine receptor activation (Talukder et al., 2002a) and the response is
endothelium-mediated through nitric oxide release (Ansari et al., 2007b). In the guinea
pig, the A2A receptor is involved in coronary vessel relaxation whereas the A2B receptor is
present predominately in the aorta (Martin et al., 1993; Shryock et al., 1998). Similarly,
the vascular effect of adenosine in aorta and coronary vessels of rat has been reported to
be mediated by both A2A and A2B receptors (Lewis et al., 1994; Lewis and Hourani,
1997).
The A2A receptor, though present in mouse aorta, has not been extensively studied
in aortic relaxation and its role in the modulation of aortic vascular responses is unclear.
This study was, therefore, undertaken to determine vascular responses mediated via the
A2A receptor. Both pharmacological tools and genetically modified mice in which the A2A
receptor was knocked out were used in the experiments. Isolated in vitro preparations of
aortic rings from A2AWT and KO mice were used to study the effects of A2A adenosine
receptors on vascular smooth muscle tone using adenosine analogs (NECA), selective
agonists (CGS 21860-A2A selective agonist; BAY 60-6583-A2B selective agonist) and
antagonists (SCH5830-A2A selective antagonist; DPCPX-A1 selective antagonist and
alloxazine-A2B selective antagonist). Gene expression of the four adenosine receptor
subtypes was also determined using aorta from both A2AWT and KO mice in real time
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RT-PCR experiments. We hypothesized that adenosine A2A receptors contributed to
adenosine-mediated vascular relaxation, in part through an endothelium-dependent
pathway. Our results indicate that the A2A receptor does contribute to aortic relaxation,
more than previously thought.

Materials and Methods
Mice
A2A KO and wild-type (WT) mice were obtained from the Institute of Experimental
Medicine (C. Ledent, Universite Libre de Bruxelles, Brussels, Belgium). To homogenize
the genetic background of the mice, the first-generation heterozygotes were bred for 14
generations on a CD1 (Charles River) outbred background, with selection for the mutant
A2A gene at each generation by PCR. Fourteenth-generation heterozygotes were bred
together to generate the A2A KO and WT. Twelve to fourteen week old males and females
were used for experiments. All experimental animals used in this study were under a
protocol approved by the Institutional Animal Care and Use Committee of West Virginia
University.

Preparation of isolated mouse aorta and isometric force measurement
Mice were sacrificed by anesthesia with pentabarbitol sodium (65 mg/kg, i.p.) followed
by thoracotomy and removal of aorta that was then cut transversely into 3-4 mm rings.
The rings were mounted vertically between two stainless steel wire hooks and then
suspended in 10 mL organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit
buffer (pH 7.4) containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM
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KH2PO4, 25 mM NaHCO3, 11 mM glucose and 2.5 mM CaCl2 was maintained at 37°C
with continuous bubbling of 95% O2 and 5% CO2. For measurement of isometric force
response, aortic rings were equilibrated for 90 min with a resting force of 1g (Tawfik et
al., 2005; Ansari et al., 2007b) and change of the bathing solution at 15 min interval. At
the end of equilibration period, tissues were contracted with 50 mM KCl to check the
contractility of individual aortic rings twice which were washed out with Krebs-Henseleit
buffer. Aortic rings were then constricted with phenylephrine (PE, 10-7M) to obtain a
steady contraction and changes in tension were monitored continuously with fixed range
precision force transducer (TSD, 125 C, BIOPAC system) connected to the differential
amplifier (DA 100B, BIOPAC system). The data were recorded using MP100, BIOPAC
digital acquisition system and analyzed using Acknowledge 3.5.7 software (BIOPAC
system).

Contraction/relaxation experiments
After equilibration, the responsiveness and stability of individual rings were checked by
successive administration of submaximally effective concentration of PE (10-7 M). The
integrity of the vascular endothelium was assessed pharmacologically by acetylcholine
(10-7 M) to produce relaxation of PE pre-contracted rings. Aortic rings were then washed
several times with Krebs-Henseleit solution, and allowed to equilibrate for 30 min before
the experimental protocol began. In experiments where the involvement of endothelium
was investigated, endothelium was removed mechanically prior to mounting in the bath,
using a thin stainless steel wire to scrape the lumen of the aorta.
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Experimental protocol
The concentration-response curves (CRCs) for NECA (10-11 -10-5 M), CGS 21860 (10-11 10-5 M) and BAY 60-6583 (10-11 -10-5 M) were run in parallel in aortic rings from A2AWT
and KO mice. In all cases, the drug was added to yield the next higher concentration only
when the response to the earlier dose reached a steady state. In experiments where the
effects of an antagonist were measured, it was added 30 min before contraction of the
tissue with PE, and was present throughout the experiments. Contraction/relaxation
responses were expressed as a percentage increase/decrease in the contraction with
respect to PE (alone) in response to each concentration of agonist used.

Real time PCR: A1, A2A, A2B, and A3 AR genes expression
The aortic tissues were processed for total RNA isolation using the TRIzol reagent from
Life Technologies/Invitrogen followed by DNase treatment to eliminate potential
genomic DNA contamination as described recently by us (Ansari et al., 2007b). This was
followed by conversion of 0.5 μg of total RNA into cDNA using High Capacity cDNA
archive kit (Applied Biosystems, Foster City, CA) in a total volume of 100 ul. Real-time
PCR was then performed using an ABI PRISM 7300 Detection System (Applied
Biosystems) using Taqman Universal Mastermix (Applied Biosystems, Branchburg, New
Jersey) according to the instructions of the manufacturer. The reaction volume (25 μL)
consisted of 12.5 μL of 2X Taqman Universal Mastermix, 1 μL of cDNA, and 1.25 μL of
20X FAM-labeled Taqman gene expression assay master mix solution. For the real-time
PCR of the concerned genes (A1AR, A2AAR, A2BAR and A3AR), the Taqman inventoried
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assays-on-demand gene expression products (Assay IDs for A3AR, A2BAR, A2AAR, and
A1AR respectively are Mm00802076_m1; Mm00839292_m1; Mm00802075_m1 and
Mm01308023_m1) were purchased from Applied Biosystems (Foster City, CA). 18S
rRNA (Ribosomal RNA) was used as an endogenous control. The fold difference in
expression of target cDNA was determined using the comparative CT method as
described earlier (Livak and Schmittgen, 2001).

Drugs used
Acetylcholine, adenosine and phenylephrine were dissolved in distilled water. 1,3Dipropyl-8-cyclopentylxanthine (DPCPX), 2-p-(2-carboxyethyl)phenethylamino-5' Nethylcarboxamido adenosine hydrochloride (CGS 21680), SCH 58261, BAY 60–6583
and 2, 4-dioxobenzo[g]pteridine (alloxazine) were dissolved in 100% DMSO as a 10 mM
stock solution. The final concentration of DMSO in organ bath (10 mL) had no effect by
itself on the aortic rings (Ansari et al., 2007b). Unless stated otherwise, all chemicals
were of the highest grade available and were purchased from Sigma Chemicals (St.
Louis, MO).

Statistical Analysis
The data were expressed as mean±SEM. Comparisons among different groups were
analyzed by ANOVA (analysis of variance) followed by Tukey’s multiple comparison
test/Bonferroni’s selected pair test. Comparison between two groups was assessed by
unpaired t-test. A p value of less than 0.05 was considered as the level of significance for
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all statistical tests. All the statistical analyses were performed using Graph Pad Prism
statistical package.
Results
Response to NECA, CGS-21680 and BAY 60–6583
The aortic relaxation/contraction responses to NECA, CGS-21680 and BAY 60-6583
were studied in A2AWT and KO mice. Organ bath data showed a concentrationdependent contraction response to NECA, a non-selective adenosine analog, in A2AKO
aorta while a biphasic concentration response was observed in A2AWT aorta (Fig. 4.1).
The maximum contraction produced by NECA (10-6 M) was 45% in KO and maximum
relaxation in WT was 25% (10-5 M). CGS-21680, a selective A2A agonist, produced a
concentration-dependent relaxation response in A2AWT aorta (30% at 10-5 M; Fig 4.2)
while BAY 60-6583, a selective A2B agonist, produced relaxation in both A2AWT and
KO aorta (38% and 33% respectively at 10-5 M; Fig 4.3). These data show that A2AWT
and KO mice had different adenosine-mediated vascular-responses, with the A2A and A2B
receptors eliciting relaxation.

Endothelial function in A2AWT and KO aorta
A2AKO mice had significantly lower (~50% relaxation) aortic endothelial response to
acetylcholine (Fig. 4.4 A) compared to the respective WT (~75% relaxation in controls)
group.
To determine the contribution of the endothelium to A2A mediated relaxation, we
next evaluated the CGS 21860 concentration-response relationship in A2A WT aortic
tissue in which the endothelium had been scraped off (-E), as described in the method
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section. Removal of the endothelium abolished CGS-21860 induced relaxation (Fig 4.4
B), suggesting the A2A receptor-mediated relaxation involved an endothelium dependent
mechanism.

Adenosine receptors gene expression in A2AWT and KO mice
To gain further insight into the pattern of adenosine receptors (AR) expression and their
involvement in vasorelaxation observed in A2AWT and KO groups, we measured aortic
gene expression of all four ARs. Real time PCR data showed that there was no difference
in receptor expression between A2AWT and KO mice (Fig 4.5). These data suggest that
the absence of the A2A receptor contributed to lower NECA-mediated relaxation in
A2AKO mice.

Effect of specific A1 AR (DPCPX), A2A AR (SCH 58261) and A2B AR (alloxazine)
antagonists on vascular reactivity in A2A WT and KO mice
Treatment of aorta with the A1 AR antagonist, DPCPX (10-5 M; Fig. 4.6) prior to
concentration response curve (CRC) with NECA resulted in concentration-dependent
vasorelaxation in A2AWT aorta with maximum relaxation being 50% at 10-5M NECA. In
A2AKO aorta, DPCPX lowered the magnitude of contraction response, however no
relaxation response was observed. The selective A2A antagonist, SCH 58261 (10-6 M)
abolished NECA- and CGS 21860-mediated relaxation, respectively, in A2AWT aorta
(Fig 4.7 A and Fig 4.7 B) while it had no effect in A2AKO tissue (data not shown).
We expected inhibition of vasorelaxation by blocking of A2B AR as it is
considered to be involved in relaxation of aorta from mice (Grbovic and Radenkovic,
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2003; Ansari et al., 2007b). Pre-treatment of aorta with the A2B AR antagonist alloxazine
(10-5 M) prior to NECA concentration-response resulted in inhibition of vasorelaxation
observed in both A2AWT and KO aorta (Fig 4.8 and Fig 4.9).

54
Figure 4.1 Concentration-response curves for NECA-mediated relaxation/contraction in
A2AWT and A2AKO mice. Values are expressed as mean ± SEM (n=8). On the ordinate,
positive and negative values indicate relaxation and contraction, respectively. *P<0.05
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Figure
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relaxation/contraction in A2AWT and A2AKO mice. Values are expressed as mean ± SEM
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Figure
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Figure 4.4 A) Endothelial response in A2AWT (~70%) and A2AKO (~50%) mice to
acetylcholine. Values are expressed as mean ± SEM (n=8). *P<0.05 B) CGS 21860
response in A2AWT endothelium denuded (-E) aorta (n=4-8)
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Figure 4.5 Adenosine receptor gene expression in A2AWT and A2AKO aorta. Values are
expressed as mean ± SEM (n=8). There was no difference in the receptor expression
levels between KO and WT mice, with the exception of the A2A receptor expression
(*P<0.05)
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Figure 4.6 Effect of the selective A1 antagonist DPCPX on NECA-mediated
relaxation/contraction in A2AWT and A2AKO mice. Values are expressed as mean ± SEM
(n=8). On the ordinate, positive and negative values indicate relaxation and contraction,
respectively. Use of DPCPX produced significantly more relaxation in A2AWT aorta
(*P<0.05) compared to the response in untreated WT tissues. In the A2AKO tissues,
DPCPX attenuated the contractile response (#P<0.05) compared to untreated KO tissues.
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Figure 4.7 Effect of the selective A2A antagonist SCH 58261 on (A) NECA- and (B)
CGS 21860-mediated relaxation/contraction in A2AWT aorta Values are expressed as
mean ± SEM (n=8). On the ordinate, positive and negative values indicate relaxation and
contraction, respectively. *p<0.05
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Figure 4.8 Effect of the selective A2B antagonist alloxazine (10-5 M) on NECA-mediated
relaxation/contraction in A2AWT mice. Values are expressed as mean ± SEM (n=8). On
the ordinate, positive and negative values indicate relaxation and contraction,
respectively. Use of alloxazine produced significantly less relaxation in A2AWT aorta
(*P<0.05) compared to the response in untreated WT tissues.
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Figure 4.9 Effect of the selective A2B antagonist alloxazine (10-5 M) on NECA-mediated
relaxation/contraction in A2AKO mice. Values are expressed as mean ± SEM (n=8). On
the ordinate, positive and negative values indicate relaxation and contraction,
respectively. Use of alloxazine produced more contraction in A2AKO aorta compared to
the response in untreated KO * P<0.05
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Discussion
The primary objective of this study was to determine whether A2A adenosine
receptors play any role in aortic vasorelaxation in mice. Our principal finding is that
A2AKO mice had lowere aortic vasorelaxation and endothelium relaxation response
compared to WT counterparts. The data indicates a role for endothelium-dependent A2A
receptor mediated vasorelaxation in mouse aorta with the A2B receptor also contributing
to aortic vascular relaxation.
The A2 receptors are involved in adenosine-dependent vasorelaxation in almost
all vascular beds studied, with the A2A and A2B contributing to the responses (Mustafa
and Askar, 1985; Ramgopal MV et al., 1988; Abebe et al., 1994; Mustafa and Abebe,
1996; Ralevic and Burnstock, 1998). In mouse aorta, high affinity A2A receptors are
present but thier role in aortic vasorelaxation has not been established, while low-affinity
A2B receptors are involved in relaxation (Talukder et al., 2002a; Ansari et al., 2007b). We
found that NECA, a non-selective adenosine analog, produced a concentration-dependent
contraction response in A2AKO aorta. Biphasic concentration response was observed in
the A2AWT counterpart, suggesting the activation of more than one receptor. This data
indicated the relaxation response produced by NECA partly involved activation of A2A
receptors as in the absence of these receptors, only contraction was observed.
We next used CGS 21680, which is a selective A2AAR agonist, and found that
A2AWT aorta displayed concentration-dependent relaxation to CGS 21860, while the
A2AKO tissue did not respond. SCH 58360, a selective A2AAR antagonist was used to
confirm the effects of CGS 21860 in activating the A2A receptors. Relaxations to CGS
21860 and NECA in A2AWT aorta were abolished with the use of the SCH compound,
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further confirming that the A2A receptor was involved in aortic relaxation. It should be
noted that while NECA is capable of activating both A2A and A2B receptors, the A2B
receptor is low affinity and may be activated only at higher concentrations of NECA
(Hussain and Mustafa, 1995; Hansen et al., 2003). The role of the A2B receptor thus could
not be ruled out.

The involvement of A2B receptors was supported by the inability of

NECA to produce relaxation in the presence of alloxazine, a selective A2B antagonist, in
A2A WT aorta while greater contraction was observed in the A2A KO aorta. Interestingly,
use of SCH 58360 in the NECA response produced steep concentration-dependent
contraction in A2A WT aorta, similar to NECA alone in A2A KO tissue. The A2B
antagonist, alloxazine, produced contraction of a lower magnitude in A2AWT aorta
compared to KO. To further explore the possibility of the A2B receptor contributing to
relaxation, concentration-response to a new and selective A2B agonist BAY 60-6583 was
obtained. At lower concentrations, no response was seen in either A2AWT or KO aorta
while at higher concentrations (10-6 and 10-5 M) relaxation was observed in both A2A WT
and KO tissues.
The A1 receptor is believed to mediate contraction in the mouse aorta (Prentice et
al., 2001; Tawfik et al., 2005). NECA has also been reported to cause contraction in
isolated carotid rings from both A2A receptor-knockout and wild-type mice and this
effect was eliminated by the selective A1 receptor antagonist DPCPX (Prentice et al.,
2002). We found that incubation of tissues with DPCPX prior to obtaining NECA
concentration-response produced a concentration-dependent relaxation response in
A2AWT aorta and abolished the biphasic response seen with NECA alone. DPCPX also
lowered the magnitude of NECA-mediated contraction observed in A2AKO. DPCPX is a

65
highly selective A1 receptor antagonist with a Ki of 3.9 nM compared with 130 for A2A,
1,000 for A2B, and 4,000 nM for A3 (Klotz et al., 1998). Our data thus confirms that the
A1 receptor mediated contraction in the A2AWT and KO aorta.
The endothelium has been shown to play an important role in adenosine mediated
relaxation as well as contraction and various studies have reported effects that are either
completely endothelium-dependent/independent, or partially endothelium-dependent in
different isolated vessels (Rubanyi and Vanhoutte, 1985; Newman et al., 1988; Yen et al.,
1988; Ansari et al., 2007b; Ansari et al., 2007a). Gauging the endothelial response in
A2AWT and KO aorta was thus important. We found the endothelial response to
acetylcholine was significantly lower in A2A KO aorta than WT. This prompted us to
further study the effect of the endothelium in the adenosine-mediated relaxation that was
observed. Mechanical removal of the endothelium totally abolished the endotheliumdependent relaxation response to acetylcholine and completely attenuated CGS 21860induced relaxation. This data provides evidence for the first time that A2A mediated aortic
vasorelaxation is endothelium dependent as CGS 21860 is a selective A2A agonist.
Studies have reported the up-regulation of the A2B receptor in coronary arteries of
A2AKO mice as a possible compensatory mechanism (Teng et al., 2008). To determine
the effect of knocking out the A2A receptor on the expression of the other adenosine
receptors in the aorta, we studied the adenosine receptor gene expression profile in
isolated aorta. These studies showed that there was no difference in the aortic expression
of the four adenosine receptors with the exception of the A2A receptor which was absent
in the A2AKO as expected. Additionally, this supports our functional data in which we
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found the selective A2B receptor agonist BAY 60-6583 produced relaxation in both
A2AWT and KO aorta that was not different.
In conclusion, the data provided here indicate a role for A2A receptors in
mediating vascular relaxation in mouse aorta. The A2B receptors also contribute to aortic
relaxation, while the A1 receptor mediates contraction. Finally, A2A mediated relaxation
appears to be completely endothelium-dependent. The exact mechanism and signaling
pathways of this endothelium-dependent response remains to be elucidated.
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CHAPTER FIVE

EVIDENCE FOR THE ROLE OF THE A1 ADENOSINE RECEPTOR IN
ALTERED VASCULAR RESPONSES AND INFLAMMATION IN ALLERGIC
MICE

Abstract
Poor lung function and respiratory disorders such as asthma have a positive
correlation with the development of adverse cardiovascular events. We hypothesize that
asthmatic lung inflammation has a systemic component and alters vascular responses
where adenosine (AD) plays an important role through A1 adenosine receptors (A1AR).
This study used a murine model of allergic asthma to investigate the effects of
aerosolized AD to elevate lung AD levels, on vascular reactivity and inflammation in
genetically modified mice, in which the A1AR was deleted (A1KO) and corresponding
wild type mice (A1WT). Both A1WT and A1KO mice were divided into 3 experimental
groups: Control (CON), allergen sensitized and challenged (SEN), and SEN+ aerosolized
AD (SEN+AD). Animals were sensitized with ragweed (200 μg, i.p.) on days 1 and 6,
followed by 1% ragweed aerosol challenges through days 11 to 13. On day 14, SEN+AD
groups received a single AD aerosol challenge (6 mg/ml) for 2 min, followed by
collection of aorta and plasma on day 15. Organ bath experiments showed concentrationdependent aortic relaxation to NECA, a non-selective adenosine analog in A1WT CON,
which was impaired in A1WT SEN and A1WT SEN+AD. All 3 groups of A1KO mice
showed concentration dependent relaxation to NECA, with no difference observed
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between A1KO CON, A1KO SEN and A1KO SEN+AD. Allergen challenge caused
systemic inflammation in allergic A1WT mice with AD aerosol further enhancing it as
determined by inflammatory cytokines profile in plasma whereas inflammation was
absent in all 3 groups of A1KO mice. A1WT allergic mice also had significantly higher
airway hyper-responsiveness (P<0.05, compared to WT CON and all A1KO groups) to
NECA, measured as Penh (enhanced pause). In conclusion, allergic A1WT mice showed
altered vascular reactivity, increased airway responsiveness and systemic inflammation,
with AD aerosol further exacerbating all these effects with A1KO mice lacking these
effects. These data suggest that A1 AR plays an important pro- inflammatory role
systemically and is responsible for altered vasoreactivity in this model of asthma.

Introduction
Asthma, a chronic lung disease, is characterized by airway hyperreactivity and
inflammation which result in bronchoconstriction and poor ventilation. Evidence has
increasingly implicated adenosine in the pathophysiology of asthma (Spicuzza et al.,
2006). Increases in adenosine levels correspond to increased airway inflammation and
tissue damage (Driver et al., 1993). A hallmark study done in the early nineteen-eighties
showed inhaled adenosine to be a potent bronchoconstrictor in asthmatics as opposed to
normal subjects who showed no response (Cushley et al., 1984). Genetically modified
mice in which adenosine deaminase (ADA), the enzyme that breaks down adenosine, was
knocked out could not survive without exogenous administration of ADA and had severe
pulmonary inflammation, airway hyper-reactivity and airway remodeling (Chunn et al.,
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2001; Blackburn and Kellems, 2005), indicating a strong correlation between chronic
elevation of adenosine levels and increased lung inflammation.
Impaired lung function is a risk factor for cardiovascular disease (Tockman et al.,
1995) and many epidemiological studies have reported that people suffering from chronic
respiratory diseases, including asthma, have a higher incidence of cardiovascular diseases
(Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et al., 2004; Knoflach et al.,
2005; Schanen et al., 2005). There is an association between atherosclerosis and stroke
with reactive airway diseases. Adult-onset asthma is associated with increased carotid
atherosclerosis in women (Onufrak et al., 2007) and subjects who had bronchial
hyperresponsiveness to methacholine demonstrated increased carotid intima-media
thickness (Zureik et al., 2004). Systemic inflammation in these patients, believed to be a
consequence of airway inflammation (Jousilahti et al., 2002; Nadeem et al., 2003), may
be one of the reasons for altered cardiovascular parameters observed (Gan et al., 2004).
Studies done in animal models of allergic asthma have also reported enhanced systemic
inflammation, myocardial ischemia-reperfusion injury and neutrophil recruitment to the
myocardium (Hazarika et al., 2004, 2007). A recent study from our lab (Ponnoth et al.,
2008) has shown that allergic mice have poor vascular responses and systemic
inflammation, with adenosine aerosol exacerbating these effects by activating A1
adenosine receptors.
The four adenosine receptor subtypes, i.e., the A1, A2A, A2B and A3, have different
modulatory roles in asthma, and the cardiovascular system (Belardinelli et al., 1989;
Mubagwa et al., 1996; Shryock and Belardinelli, 1997). Many reports suggest that the A1
adenosine receptor is involved in direct bronchoconstrictor effects of adenosine. A1
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receptor expression was found to be elevated in a rabbit model of asthma and the use of
an A1 antisense nucleotide to inhibit this upregulation resulted in blunted
bronchoconstriction to adenosine (Nyce and Metzger, 1997; Abebe and Mustafa, 1998).
Use of a selective A1 antagonist produced

significant reduction of

airway hyper-

responsiveness in allergic rabbits by blocking these receptors (Obiefuna et al., 2005). A
very recent study reported that the expression of A1 receptor is significantly elevated in
airway smooth muscle in asthmatic patient (Brown et al., 2008). Other than the effects
on airway smooth muscle, the A1 receptor has been implicated in increased mucin
production in human tracheal cells (McNamara et al., 2004) and in mediating monocyte
phagocytosis (Salmon et al., 1993). All these studies suggest a strong role for the A1
receptor in asthma, both in airway obstruction and inflammation
A1 receptors also have systemic effects and are involved in blood pressure
regulation (Brown et al., 2006) and vasoconstriction (Shepherd et al., 1996; Talukder et
al., 2002b; Hansen et al., 2003; Tawfik et al., 2005). However, the role of the A1AR in
the control of vascular tone and systemic inflammation in an allergic model of asthma has
not been characterized. In addition, the vascular effects of A1 receptors in response to
exogenous adenosine challenge as an added insult in a murine model of asthma have not
been studied previously. Therefore, this study was undertaken to investigate the effects of
allergen challenge and inhaled adenosine on vascular reactivity and systemic
inflammation using our murine model of asthma in A1WT and KO mice. We also
determined the role of the A1AR in airway responsiveness by whole body
plethysmography. Our data suggest that asthmatic A1WT mice have altered peripheral
vascular reactivity, systemic inflammation and increased bronchoconstriction with
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inhaled adenosine further exacerbating these effects, compared to A1KO mice, in which
these responses were not elicited.

Materials and Methods
Animals: Balb/c mice (A1WT) 8-10 weeks old males were obtained from Harlan Sprague
Dawley

(Indianapolis, IN) and A1KO mice were obtained from Stephen Tilley,

Pulmonary and Critical Care, School of Medicine, University of North Carolina, Chapel
Hill. The animals were maintained on a ragweed-free diet. All experimental animals used
in this study were under a protocol approved by the Institutional Animal Care and Use
Committee of West Virginia University.

Animal sensitization: Sensitization was performed according to the protocol described
earlier from this laboratory (Fan and Mustafa, 2002; Fan et al., 2003; Oldenburg and
Mustafa, 2005; Fan and Mustafa, 2006; Mustafa et al., 2007). This model of allergic
asthma has been shown to develop airway inflammation and airway hyper-reactivity to
methacholine. The study comprised of six groups of animals: a) A1WT Control (A1WT
CON); b) A1WT Allergen sensitized and challenged (A1WT SEN); c) A1WT Allergen
sensitized and challenged further with 6 mg/ml of adenosine aerosol for 2 min on day 14
(A1WT SEN+AD); d) A1KO Control (A1KO CON); e) A1KO Allergen sensitized and
challenged (A1KO SEN); f) A1KO Allergen sensitized and challenged further challenged
with 6 mg/ml of adenosine aerosol for 2 min on day 14 (A1KO SEN+AD). Experiments
carried out previously with A1WT CON mice subject to adenosine challenge (A1WT
CON+AD) showed that this group was not different from A1WT CON and, hence, this
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group was not included for further experimentation. Mice were sensitized on days 1 and 6
with i.p. injections of ragweed allergen (Greer Laboratories, Lenoir, NC), 200 µg per
dose with 200 µL Imject Alum (Pierce Laboratories, Rockford, IL). Non-sensitized
control animals received only the Imject alum with the same volumes. 10 days after
sensitization, the mice were placed in a Plexiglas chamber and challenged with 1%
aerosolized ragweed or with 0.9% saline as a control, using an ultrasonic nebulizer
(DeVilbiss Somerset, PA) for 20 minutes both in the morning and afternoon for three
consecutive days. The aerosolization of allergen was performed at a flow rate of 2
mL/min, and the aerosol particles had a median aerodynamic diameter of less 4 µm (De
Vilbiss).
Acute elevations in lung adenosine levels were produced experimentally by
adenosine inhalation (6 mg/ml for 2 min on day 14) to SEN+AD group to further enhance
allergen-induced effects. This dose was chosen based on our previous studies in this
model (Fan and Mustafa, 2002; Fan and Jamal Mustafa, 2006). Adenosine inhalation in
this model has been shown to enhance allergen-induced airway inflammation and airway
hyper-reactivity to adenosine (or its analog NECA) (Fan and Mustafa, 2002; Fan et al.,
2003; Fan and Mustafa, 2006). ADA-deficient mice having sustained and chronic
elevations in lung adenosine levels have also been shown to have similar features (Chunn
et al., 2001). We chose 24 hr post-adenosine inhalation for our current studies based on
an earlier study from our lab which showed maximum eosinophilic inflammation in
airways after 24 hr of adenosine inhalation (Fan and Mustafa, 2006), which is a hallmark
of asthmatic inflammation. CON and SEN groups received only saline on day 14.
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Twenty-four hours after the last challenge, animals were sacrificed for collection of aorta
and blood for further experiments.

Preparation of isolated mouse aorta and isometric force measurement
Mice were sacrificed by anesthesia with pentabarbitol sodium (65 mg/kg, i.p.) followed
by thoracotomy and removal of aorta that was then cut transversely into 3-4 mm rings.
The rings were mounted vertically between two stainless steel wire hooks and then
suspended in 10 mL organ baths containing Krebs-Henseleit buffer. The Krebs-Henseleit
buffer (pH 7.4) containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 25 mM NaHCO3, 11 mM glucose and 2.5 mM CaCl2 was maintained at 37°C
with continuous bubbling of 95% O2 and 5% CO2. For measurement of isometric force
response, aortic rings were equilibrated for 90 min with a resting force of 1g that has
been used earlier in our laboratory (Tawfik et al., 2005; Ansari et al., 2007b) and change
of the bathing solution at 15 min interval. At the end of equilibration period, tissues were
contracted with 50 mM KCl to check the contractility of individual aortic rings twice
which were washed out with Krebs-Henseleit buffer. Aortic rings were then constricted
with phenylephrine (PE, 10-7 M) to obtain a steady contraction and changes in tension
were monitored continuously with fixed range precision force transducer (TSD, 125 C,
BIOPAC system) connected to the differential amplifier (DA 100B, BIOPAC system).
The data were recorded using MP100, BIOPAC digital acquisition system and analyzed
using Acknowledge 3.5.7 software (BIOPAC system).
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Contraction/relaxation experiments
After equilibration, the responsiveness and stability of individual rings were checked by
successive administration of submaximally effective concentration of PE (10-7 M). The
integrity of the vascular endothelium was assessed pharmacologically by acetylcholine
(10-7 M) to produce relaxation of PE pre-contracted rings. Aortic rings were then washed
several times with Krebs-Henseleit solution, and allowed to equilibrate for 30 min before
the experimental protocol began.

Experimental protocol
The concentration-response curves (CRCs) for NECA (10-9 -10-5 M) were run parallel in
aortic rings from all the groups. In all cases, NECA was added to yield the next higher
concentration only when the response to the earlier dose reached a steady state.
Contraction/relaxation responses were expressed as a percentage increase/decrease in the
contraction with respect to PE (alone) in response to each concentration of agonist used.

Assessment of systemic inflammation
Mice were euthanized by pentobarbitone sodium (65 mg/mL, i.p.), followed by collection
of blood by cardiac puncture in heparinized syringes. The blood collected from different
groups was centrifuged at 800 g for 10 min at 4° C and the resulting plasma was used for
cytokine assays.
Multiplex cytokine assay: Cytokine assay of IL-5, TNFα and IL-13 in the plasma was
measured by a commercial kit from Linco Research (St. Charles, Missouri) using the
Luminex 200 system (Luminex Corp., Austin, Tx), which is a multianalyte bioassay
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detection system capable of performing up to 100 assays simultaneously in a single
microtiter plate well. This system uses polystyrene microspheres internally dyed with red
and infrared fluorophores that can be individually identified. The fluorescent
microspheres were coated with capturing antibodies specific for different chemokines.
The chemokine-captured beads after incubation with the sample were then mixed with
phycoerythrin-conjugated detection antibodies to form immune complexes. Following
incubation, washing and acquisition of fluorescence data, the concentration results were
generated in graphical format using the standard curve generated for each cytokine.
Results were expressed in pg/mL.

Airway responsiveness to Methacholine (MCh) and NECA
The airway responsiveness was assessed by whole body plethysmography using the
chambers obtained from Buxco Inc. (Max II; Buxco Systems, Wilmington, NC). This
system enables the measurement of airway obstruction using a dimensionless parameter
called enhanced pause or Penh. Higher the Penh values, greater is the airway obstruction.
Penh has been shown to correlate with airway resistance and dynamic compliance
(Justice et al., 2001). Unrestrained mice were placed in individual Plexiglas chambers
twenty four hours after the last allergen challenge and subjected to increasing
concentrations of MCh (1.5-48.0 mg/ml) to obtain concentration-responses. In case of
SEN+AD groups, this was 24 hours post adenosine aerosolization. Concentrationresponses to NECA were performed 24 hours post the MCh experiment. After obtaining
baseline and vehicle Penh values, mice were exposed to increasing concentrations of
NECA (23.44-750 µg/ml) via the Buxco aerosol delivery system (version 1.5; Buxco,
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Wilmington, NC). Each concentration of NECA was aerosolized for 2 minutes and the
Penh readings were recorded for 5 minutes to establish a dose-response relationship. The
next dose was not administered until the mice had returned to baseline Penh levels.
Airway responsiveness was normalized to the vehicle control (normal saline) and
expressed as a percentage increase in Penh.

Drugs used
Acetylcholine, adenosine and phenylephrine were dissolved in distilled water. 5’-Nethylcarboxamidoadenosine (NECA) was dissolved in 100% DMSO as a 10 mM stock
solution for vascular reactivity experiments. The final concentration of DMSO in organ
bath (bath volume: 10 mL) had no effect by itself on the aortic rings (Ansari et al.,
2007b). For Penh responses, MCh was dissolved in 0.9% saline and NECA was dissolved
in 100% ethanol to create a stock solution from which subsequent dilutions were made
with 0.9% saline. Unless stated otherwise, all chemicals were of the highest grade
available and were purchased from Sigma Chemicals (St. Louis, MO).

Statistical Analysis
The data were expressed as mean± SEM. Comparisons among different groups were
analyzed by ANOVA (analysis of variance) followed by Tukey’s multiple comparison
test/ Bonferroni’s selected pair test. Comparison between two groups was assessed by
unpaired t-test. A p value of less than 0.05 was considered as the level of significance.
All statistical analyses were performed using the GraphPad Prism statistical package.
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Results
Systemic inflammation in control, allergic and adenosine aerosolized allergic mice
Table 5.1 shows the multiplex cytokine profile in all the groups. Allergen challenge
significantly increased plasma levels of inflammatory cytokines IL-5 and IL-13 in A1WT
SEN as compared to A1WT Con and all groups of A1KO mice. Allergen sensitized and
challenged A1WT mice exposed to adenosine aerosol (SEN+AD) had the highest level of
the pro-inflammatory cytokines compared to other groups. Other cytokines in the panel
were either undetectable or not different among the groups (data not shown). These data
suggest activation of the A1 receptor has pro-inflammatory effects.

Vascular reactivity in control, allergic and allergic + adenosine groups
The aortic relaxation/contraction responses to NECA were studied in all 6 groups. Organ
bath data showed a concentration dependent relaxation response to NECA in A1WT
CON, while aortic relaxations were impaired in A1WT SEN aorta with a maximum
relaxation of 7% (Fig 5.1 A). NECA failed to elicit any relaxation response in SEN+AD;
it produced a concentration dependent contractile response, with a maximum contraction
of 35% at 10-6 M (Fig 5.1 A). In contrast, all 3 groups of KO mice showed concentrationdependent relaxation and there was no difference in the responses between the groups
(Fig 5.1 B). These data show that allergen sensitization and challenge altered the vascular
reactivity with adenosine aerosol further exacerbating it in allergic A1WTmice, indicating
that the A1 receptor was responsible for the low adenosine-mediated vascular relaxation
observed. Comparison between respective groups of SEN and SEN+AD WT and KO
groups are shown in figures 5.2 and 5.3.
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Endothelial function in control, allergic and allergic + adenosine groups
Figure 5.4 shows the endothelial response to ACh in all experimental groups. A1WT SEN
(~39%) and SEN+AD (~38%) groups had significantly lower (P<0.01) endothelial
response to acetylcholine compared to WT controls (~65% relaxation). There was no
difference in endothelial response between any group of A1KO mice and between the KO
groups and A1WT CON; however A1KO SEN and A1KO SEN+ AD had significantly
higher endothelial relaxation than A1WT SEN and A1WT SEN+ AD groups (P<0.05)
These data show that allergen challenge probably led to endothelial dysfunctional in
allergic A1WT mice.

Airway responsiveness to Methacholine (MCh) and NECA
The airway responsiveness to MCh (Fig 5.5) was assessed and there was no difference
between control A1WT and KO mice. All groups of sensitized mice WT and KO had
significantly increased airway response to MCh compared to respective controls but there
was no difference between sensitized A1WT and KO mice. Next, the response to NECA
was assessed (Fig 5.6). Although baseline Penh values for control A1WT (284.05 ± 65.4)
were higher than A1KO (180.36 ±22.52), the difference was not statistically significant.
However, allergic A1WT SEN and A1WT SEN+AD mice had significantly higher airway
responsiveness, with the response being highest in the A1WT SEN+AD group. In
contrast, A1KO SEN and SEN+AD groups had comparable response to A1KO CON
group. These data indicate that adenosine mediated hyper-responsiveness is mediated
through the A1 receptor.
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Table 5.1: Systemic inflammation as assessed by levels of inflammatory cytokines in
plasma of A1WT and A1KO control (CON), allergic (SEN) and adenosine aerosolized
allergic (SEN+AD) mice; Values are expressed as Mean ± SEM (n=4-8). *P<0.05
compared to A1WT CON; #P<0.05 compared to A1WT SEN.

INFLAMMATORY
MARKER (pg/ml)

CON

SEN

SEN+AD

A1WT

A1KO

A1WT

A1KO

A1WT

A1KO

IL-5

3.35±0.14

3.98±0.93

8.22±1.65*

4.078±0.57

11.12±1.5*

3.88±1.50

IL13

27.44±5.57 UNDETECTED 45.41±9.91* UNDETECTED 170±49.97*# UNDETECTED

TNF-α

6.66 ±1.03 UNDETECTED 6.25±0.23

UNDETECTED 14.22±3.60*# UNDETECTED
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Figure 5.1 Concentration-response curves for NECA-mediated relaxation/contraction in
A1WT (A) and A1KO (B) with control (CON), allergic (SEN) and adenosine aerosolized
allergic (SEN+AD) groups. Values are expressed as mean ± SEM (n=4). On the ordinate,
positive and negative values indicate relaxation and contraction, respectively. *P<0.05 as
compared to CON; $ P<0.05 as compared to SEN.
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Figure 5.2 Comparison between A1KO and A1WT sensitized mice. Values are expressed
as mean ± SEM (n=4). On the ordinate, positive and negative values indicate relaxation
and contraction, respectively. *P<0.05
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Figure 5.3 Comparison between A1KO and A1WT SEN+AD mice. Values are expressed
as mean ± SEM (n=4). On the ordinate, positive and negative values indicate relaxation
and contraction, respectively. *P<0.05

A1WT vs A1KO

% RELAXATION

75

A1WT SEN+AD
A1KO SEN+AD

50

*
*

25

*

0

*

*

-25
-50
-10

-9

-8

-7

-6

NECA (log M )

-5

-4

83
Fig 5.4 Endothelial response to ACh in CON, SEN and SEN+AD A1WT and A1KO
mice. A1WT SEN and SEN+AD groups were significantly different from A1WT CON
*P<0.01 and A1KO SEN, SEN+AD #P<0.05
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Figure 5.5 Airway responsiveness to MCh in A1KO and A1WT mice. Values are
expressed as mean ± SEM (n=4-8). On the ordinate, airway response is expressed as % of
the vehicle. *P<0.05 A1WT SEN and SEN+AD compared to A1WT CON; # P<0.05
A1KO SEN and SEN+AD compared to A1KO CON
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Figure 5.6 Airway responsiveness to NECA in A1KO and A1WT mice. Values are
expressed as mean ± SEM (n=4-8 ). On the ordinate, airway response is expressed as %
of the vehicle. *P<0.01 compared to A1KO CON; $P<0.01 compared to A1KO SEN; #P<
0.05 compared to A1KO SEN+AD; %P<0.05 compared to A1WT SEN, @P<0.05
compared to A1WT CON.
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Discussion
The principal finding of the present study is that allergic A1WT mice had
systemic inflammation, increased airway responsiveness and impaired vasorelaxation to
NECA, a non-selective adenosine analog. These outcomes were further aggravated after
acute adenosine aerosol challenge in these mice. Responses in allergic A1KO mice were
not different from non-allergic wild type controls, indicating that the A1 adenosine
receptor was responsible for alterations in vascular reactivity, airway hyperresponsiveness and increased inflammation. Administration of NECA caused increased
airway responsiveness in allergic A1WT mice which was absent in corresponding A1KO
mice. Endothelium was found to be dysfunctional in allergic A1WT mice compared to
non-allergic A1WT controls, while both allergic and non-allergic A1KO mice had no
difference in endothelial responses.
Adenosine is chronically elevated in asthmatic lungs (Mann et al., 1986b; Mann et
al., 1986a; Driver et al., 1993). Evidence indicates adenosine may be involved in the
release of inflammatory mediators in the lung and systemic circulation by acting on its
receptors present on different cells including mast cells, eosinophils, neutrophils and
other inflammatory cells (Driver et al., 1991; Fan and Jamal Mustafa, 2006; Nadeem and
Mustafa, 2006; Spicuzza et al., 2006) and can thus contribute to the severity of lung
inflammation. Adenosine is a known bronchoprovocant (Cushley et al., 1983) and
experimentally induced temporary elevations in lung adenosine levels through inhalation
of adenosine (resulting from breakdown of adenosine 5'-monophosphate) cause an
increase in infiltration of eosinophils in patients with asthma (van den Berge et al., 2004).
A recent study from our lab has also shown increased release of inflammatory cell
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markers in the lung and plasma after inhalation of adenosine aerosol in allergic mice (Fan
and Mustafa, 2002). However, the systemic effects of such an inhalation with respect to
involvement of specific adenosine receptors have not been studied previously. Adenosine
aerosol in human asthmatics causes increased release of neutrophil chemotactic factor in
serum (Driver et al., 1991). These studies suggest that adenosine enhances the release of
systemic inflammatory mediators from inflammatory cells
Systemic inflammation has been reported previously in human asthmatics and
animal models of asthma (Jousilahti et al., 2002; Hazarika et al., 2004). Neutrophils and
eosinophils are increased in bronchoalveolar lavage and blood in a murine model of
asthma (Hazarika et al., 2007). Systemic inflammatory markers have also been shown to
be elevated in patients with asthma and in allergic mouse model of asthma after
adenosine aerosol challenge. (Driver et al., 1991; Fan and Jamal Mustafa, 2006). Based
on the findings of these studies, we investigated the cytokine profile in systemic
circulation in allergic A1WT and A1KO mice. We found that while allergic A1WT mice
had significantly elevated levels of pro-inflammatory cytokines, allergic A1WT mice
exposed to acute adenosine aerosol had further exacerbation of systemic inflammation as
evidenced by the finding that several pro-inflammatory cytokines levels (IL-13, MCP-1,
and TNF-α) were increased most in this group. In A1KO mice, both allergic and control
groups either had undetected or non-significant levels of inflammatory markers,
suggesting the absence of the A1 receptor was related to lower inflammation. From the
mediator profile, IL-13 was significantly higher in the plasma of A1WT SEN mice, with
adenosine challenge exacerbating it even further. IL-13 is an important mediator in
asthma and has been implicated in lung inflammation, airway remodeling and airway
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hyperreactivity (Grunig et al., 1998; Lowry et al., 2008). Adenosine and IL-13 interact
positively, with each increasing the levels of the other in studies done with asthmatic
mice (Blackburn et al., 2003). IL-13 and adenosine thus are important in lung
inflammation but their role in systemic inflammation is not known. Our data suggest a
pro-inflammatory role for IL-13 and adenosine mediated systemic inflammation via the
A1 receptors.
Asthma has been associated with an increased incidence of negative
cardiovascular outcomes (Drislane et al., 1987; Toren and Lindholm, 1996; Iribarren et
al., 2004; Knoflach et al., 2005). While asthmatic inflammation is believed to responsible
for the development of these cardiovascular effects, there is little information linking the
two, especially in relation to the vascular effects of specific adenosine receptors. In the
present study, NECA, a non-selective adenosine analog produced a concentrationdependent vasorelaxation in control A1WT mice, which was impaired in allergic A1WT
mice. Vascular reactivity to NECA was further altered in aorta of allergic A1WT mice
that had received aerosolized adenosine. In contrast, NECA produced a concentrationdependent vasorelaxation response in allergic and non-allergic A1KO groups. These
findings strongly suggest that the A1 receptor indeed is responsible for poor vascular
responses in allergic mice.
In a recent study from this laboratory, we found that allergic mice had lower
endothelial relaxation suggesting that allergen exposure and development of allergic
asthma somehow resulted in endothelial dysfunction (Ponnoth et al., 2008). In the present
study, we observed that there was no difference in the endothelial response between
control and allergic A1KO mice as opposed to significantly lower endothelial relaxation
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in allergic A1WT mice compared to A1WT controls. The exact cause for this dysfunction
is not clear but it could possibly be due to the A1 receptor-mediated increase in systemic
inflammatory cytokines. These inflammatory cytokines are known to suppress eNOS and
nitric oxide production (Cardaropoli et al., 2003; Li et al., 2004). For the first time, the A1
receptor specifically has been shown to affect the endothelium functionality in allergic
mice. Further studies are required to delineate the exact mechanism for the role of the
A1AR in alteration of endothelial function especially the signaling pathways that may be
involved.
Whole body plethysmography has been used previously to determine the extent of
airway responsiveness and as an index of airway obstruction (Drazen et al., 1999; Fan
and Mustafa, 2002; Fan et al., 2003; Oldenburg and Mustafa, 2005). We used this method
to determine the differences between A1WT and KO responses to MCh and NECA. MCh
produced higher airway responsiveness in both A1WT and KO sensitized animals
compared to controls. No difference was observed between A1WT and KO mice.
However, the response to the non-selective adenosine analog NECA was different
between A1KO and WT mice. There was no difference in NECA-mediated airway
response in all three groups of A1KO mice, while A1WT SEN mice had significantly
higher responses. The highest response was observed in A1WT SEN+AD, which was
significantly different from all other study groups. The A1 receptor has been implicated
in the direct adenosine-mediated bronchoconstrictor response (Nyce and Metzger, 1997;
Abebe and Mustafa, 1998) and a selective A1 antagonist produced significant reduction
of airway hyper-responsiveness in allergic rabbits by blocking these receptors (Obiefuna
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et al., 2005).

Our data supports a role for A1 receptor-mediated airway

hyperresponsiveness and also shows that adenosine challenge exacerbates the response.
In conclusion, our findings provide evidence for the first time that the A1
adenosine receptor mediates alterations in systemic parameters (inflammation, lower
endothelial response and impaired vasorelaxation) and airway hyper-responsiveness as a
result of allergen exposure and adenosine aerosol challenge in sensitized mice.
Understanding the exact contribution of adenosine and adenosine A1 receptor mediatedsystemic effects with respect to mechanisms and signal transduction would provide an
important tool in the prevention of systemic inflammation and harmful systemic side
effects in designing therapies for asthma. Ultimately, this could be beneficial in lowering
cardiovascular events in asthmatics.
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CHAPTER SIX

CONCLUSION

The work presented in this dissertation establishes that asthma has
detrimental effects beyond lungs and airways in allergic mice. Systemic inflammation,
endothelial dysfunction and altered vascular reactivity appear to be associated with
asthma. Adenosine plays an important role in these effects and exogenously administered
adenosine to increase the lung levels experimentally beyond the allergen exposure
exacerbates observed outcomes.
Specific adenosine receptors are involved in the vascular responses seen, with
different receptors modulating beneficial and detrimental effects. Vascular A2A and A2B
receptors are down-regulated in allergic mice, and this was confirmed with the use of the
specific receptor antagonists. To get a better insight into the role of A2A receptors on
aortic tone, vascular responses to various adenosine analogs were studied in A2A receptor
knock-out and wild type mice that were non-allergic.
In vitro aortic relaxation in A2AWT mice was a biphasic response to NECA, a
non-selective adenosine analog, while the response in A2AKO tissue was concentrationdependent contraction. This indicated the possibility that the absence of A2A receptor as
being responsible for contraction. A2AKO mice also had lower endothelial relaxation than
their wild-type counterparts, which suggested that relaxation through A2A receptors
occurred via an endothelial dependent mechanism. Use of the A1 antagonist (DPCPX)
increased the relaxation in A2AWT mice while the contraction observed in A2AKO mice
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was reduced although relaxation was still absent. This again underscored a role for the
A2A receptor in relaxation while confirming that the A1 receptor was responsible for
adenosine-mediated contraction. These studies determined that the A2A receptor mediates
vasorelaxation in the aorta in conjunction with the A2B receptor.
The next aim of the study was to determine the exact role of the A1 receptor in the
allergic model. The reason for focusing on the A1 receptor came about from the initial
study when it was found that the use of DPCPX (selective A1 receptor antagonist)
restored aortic relaxation in allergic mice comparable to non-allergic controls. The A1
receptor was also found to be up-regulated in the aorta from allergic mice further
subjected to adenosine aerosol.
Genetic knock-out mice were used to study and confirm the involvement of A1
receptor. Data showed that the allergic A1WT mice had lower adenosine-mediated aortic
relaxation, significantly higher levels of inflammatory markers in the plasma and
increased airway responsiveness. These outcomes were exacerbated in allergic A1WT
mice that had received exogenous adenosine as a single aerosol inhalation. In contrast, no
impairment in adenosine-mediated vascular responses were observed in A1KO (allergic
and non-allergic controls) aortic tissue. There were significantly lower (or undetectable)
levels of inflammatory markers and lower airway responsiveness to NECA in A1KO
mice. In fact, there was no difference between allergic A1KO and control A1KO mice.
These data implicate the A1 receptor as having deleterious systemic and airway effects in
allergic mice. The systemic effects appear to be the result of inflammation. However, the
exact signaling mechanism(s) of the A1 involved in translation of airway inflammation to
the observed systemic outcomes is not known and remains to be studied.
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Future Direction
The next step in this model of asthma would be to define the adenosine receptor
signaling mechanisms involved. Our preliminary data show that asthmatic mice have
both lung as well as systemic inflammation. It is important to have a better understanding
of this correlation and the possible signaling pathways involved. Based on the data in this
dissertation that shows highest levels of IL-13 in allergic mice, and review of literature
which has established a close relationship between IL-13 and adenosine in lung
inflammation, the next focus could the potential role for this inflammatory cytokine as an
intermediary signaling molecule, both in asthma and cardiovascular disease.
IL-13 is an important mediator in asthma and has been implicated in lung
inflammation and airway remodeling. It is a product of mast cell degranulation and is
also released from T-helper 2 (Th2) cells. Adenosine and IL-13 interact with each other
in a positive feedback in studies done with asthmatic mice (Blackburn et al., 2003).These
authors found that IL-13 caused a progressive increase in adenosine accumulation,
inhibited the activity of adenosine deaminase, and augmented the expression of the A1,
A2B, and A3 adenosine receptors. Their findings suggest that adenosine signaling
contributes to and influences the severity of IL-13 induced tissue responses.
IL-13 signaling occurs through the Janus kinase (JAK)/signal transducer and
activator of transcription (STAT) pathway. This cytokine acts on its receptor (via JAK-1)
and leads to phosphorylation of STAT6, which induces the transcription of several genes
including 5-lipoxygenase (LO).

5-LO, via the arachidonic acid pathway, produces

inflammatory leukotrienes (LTs) which are very important mediators of IL-13 induced
lung injury. Recent studies have also suggested a pro-atherosclerotic role for LTs with
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LTB4 acting as a potent leukocyte chemoattractant that amplifies inflammation at
atherosclerotic sites (M.Back et al., 2005).
Other than LTs, studies in asthma have shown that IL-13 also induces vascular
endothelial growth factor (VEGF) from human airway smooth muscle cells, mast cells,
epithelial cells and macrophages (Faffe et al., 2006). In fact, IL-13 and VEGF act on each
other in positive feedback loops. VEGF and VEGF receptor inhibitors reduce lung
inflammation and airway hyper-reactivity in asthma (Faffe et al., 2006). This study also
found that over expression of VEGF enhances Th2-mediated sensitization and
inflammation. Studies involving human atherosclerosis have noted that VEGF is thought
to play a pro-atherosclerotic role. VEGF is an angiogenic factor. It induces migration and
proliferation of endothelial cells and enhances vascular permeability. It has been reported
that human coronary atherosclerotic plaques were positive for VEGF mRNA but not so in
normal arterial tissues (Inoue et al., 1998).
IL-13 and IL-4 act synergistically with TNF-α to increase eotaxin levels in the
lungs. Eotaxin increases lung eosinophilia in asthma and is very important in
amplification of eosinophilic inflammation. Though eosinophilia is considered to be a
characteristic hallmark of asthmatic inflammation, eosinophils are not found in any
significant amounts in atherosclerotic lesions. However, eotaxin may have a novel role in
atherosclerosis that does not involve eosinophils. Haley et al. have reported that eotaxin
and its receptor, CCR3, were overexpressed in the inflammatory infiltrate of human
atheroma (Haley et al., 2000). CCR3 was predominantly expressed on macrophages and
they suggest eotaxin may participate in mast cell activation or recruitment.
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Data in this dissertation show that systemic levels of IL-13 are increased
significantly in allergic A1WT mice compared to non-asthmatic controls. Interestingly,
allergic A1KO did not have any increase in IL-13, suggesting a role for the A1 receptor.
The next step would be to determine if IL-13 does, in fact, have a role in vascular
inflammation and the signaling mechanism involved. Ultimately, understanding the
signaling pathway (s) involved would lead to uncovering of the translational mechanism
(s) of lung inflammation to systemic effects in human asthma.
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Figure 6.1: Proposed pathway for IL-13 signaling effects in asthma
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APPENDIX A

The relaxation response to NECA was calculated at two different concentrations of
phenylephrine (PE) used to pre-contract tissues. This was done to determine the
concentration of PE to be used for experiments. There was no difference in NECA
mediated relaxation in tissues precontracted with 0.1µM and 1 µM of PE respectively.
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The relaxation response to adenosine was calculated at two different concentrations
phenylephrine used to pre-contract tissues. This was done to determine the concentration
of PE to be used for experiments. There was no difference in adenosine mediated
relaxation in tissues precontracted with 0.1µM and 1 µM of PE respectively.
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The endothelial response to acetylcholine was determined at two different concentrations
phenylephrine (PE) used to pre-contract tissues. This was done to determine the
concentration of PE to be used for experiments. There was no difference in adenosine
mediated relaxation in tissues precontracted with 0.1µM and 1 µM of PE respectively.
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APPENDIX B

Preliminary experiments (airway responsiveness and vascular reactivity) were carried out
with ovalbumin-sensitized and challenged A2AWT and A2AKO mice that had also
received aerosolized adenosine challenge. A2AKO mice had increased airway
responsiveness as seen from the Penh data and reduced aortic relaxation to NECA
compared to wild-type counterparts. However, adenosine mediated aortic vascular
responses in naïve (non-allergic) mice were not known, which led to studying of vascular
reactivity in A2AWT and A2AKO mice (Chapter 4)
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A2A SEN + AD
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APPENDIX C
Level of inflammatory cytokines in bronchoalveolar lavage fluid was measured in control
(CON), ragweed sensitized (SEN) and ragweed sensitized +aerosolized adenosine Balb/c
mice to determine the difference in lung inflammation. Sensitized mice that had received
the additional adenosine aerosol challenge had the highest level of inflammatory
cytokines.
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